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Abstract  
 
 
Considerable attempts have been made to produce adequate matrices or scaffolds that mimic 
the natural extracellular matrices (ECM). If functionalized with active agents (molecules, growth 
factors or proteins) the synthetic biomimetic ECM’s are capable to enhance cell response in 
tissue engineering and regenerative medicine. 
This PhD project aimed at designing a novel biocomposite mimicking natural bone ECM through 
innovative approaches based on simultaneous type I collagen electrospinning and nanophased 
hydroxyapatite (nanoHA) electrospraying using non-denaturating conditions and non-toxic 
reagents. The diameter of the electrospun collagen nanofibers under 100 nm, are far below by 
those generally described in the literature, thus offering a roadmap to obtain a further level of 
biomimicry to matrix design strategies. The network architecture allows cell access to both 
collagen nanofibers and HA crystals, as in natural bone environment.  
Another goal of this work was to evaluate the impact of SPARC (secreted protein, acidic and 
rich in cysteine) in Prostate cancer (PCa), the second most incident cancer in men worldwide, 
and bone metastization. The expression and activity of SPARC is correlated with metastatic 
dissemination ability of PCa cells into bone. Therefore a better understanding of the biological 
mechanisms underlying SPARC involvement in PCa will most likely contribute to improved 
clinical approach and therapeutic decision. This was explored by assessing morphology, 
metabolic activity, and SPARC expression in different PCa cell lines, resembling different 
stages of prostate carcinogenesis cultured on a SPARC functionalized 3D bone-like model 
based on the novel biocomposite mimicking natural bone extracellular matrix. Furthermore, 
quantum dots were directly functionalized by chitosan-SPARC bioconjugates aiming at 
bioimaging and internalization towards tumor cells. Our findings highlight distinct cellular 
behavior depending on PCa cell line type and presence of exogenous SPARC. In fact, SPARC 
addition contributed to the survival and significant growth of a non-bone metastatic PCa cell line 
(LNCaP) on bone-like construct. Moreover, SPARC expression was evaluated in an extensive 
series of prostatic tissue samples from both normal and tumor samples. Remarkably, SPARC 
was overexpressed in patients with higher Gleason Score, indicating undifferentiated tumors 
with poor prognosis. Likewise, SPARC was more expressed in metastasis compared with their 
respective primary tumors, particularly from bone sites.  
In summary, a novel biomaterial based on collagen nanofibers and nanoHA agglomerates was 
obtained by co-electrospinning/electrospraying being a promising candidate for bone tissue 
applications such as bone defects healing, or as a functionally membrane for guided bone 
tissue regeneration and the treatment of further bone diseases. Furthermore, this innovative 3D 
bone mimetic biomaterial immobilized with SPARC was applied as an in vitro model for 
providing insight into SPARC relevance on prostate carcinogenesis and bone metastization. 
This work suggests a potential role of SPARC as a clinical target on PCa, due to its association 
with bone metastization. 
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Resumo 
 
 
Inúmeros esforços têm sido realizados no sentido de produzir matrizes ou estruturas 
tridimensionais (3D) que mimetizem as matrizes naturais extracelulares (MEC). Uma vez 
funcionalizadas com agentes ativos (moléculas, fatores de crescimento ou proteínas) estas 
MEC biomiméticas sintéticas são capazes de aumentar a resposta celular em engenharia de 
tecidos e em medicina regenerativa.  
Um dos objetivos deste projeto de doutoramento consistiu no desenvolvimento de um novo 
biocompósito que mimetize a MEC natural do osso através de uma abordagem inovadora, 
englobando a aplicação em simultâneo de electrospinning de colagénio tipo I e de 
electrospraying de hidroxiapatite nanofásica (nanoHA) sob condições não-desnaturantes e 
utilizando reagentes não-tóxicos. As nanofibras de colagénio obtidas por electrospinning têm 
um diâmetro inferior a 100 nm, claramente inferior aos descritos na literatura, abrindo assim um 
leque de possibilidades na produção mais avançada de matrizes biomiméticas. A arquitetura 
desta malha permite que as células tenham acesso a ambos os componentes, isto é, quer às 
nanofibras de colagénio quer aos cristais de HA, tal como acontece no ambiente natural do 
osso.  
Outro objetivo deste trabalho foi avaliar o impacto da SPARC (secreted protein, acidic and rich 
in cysteine) no cancro da Próstata (CaP), o segundo cancro mais frequente na população 
masculina em todo o mundo, e na metastização óssea. A expressão e atividade da SPARC 
estão relacionadas com a capacidade de disseminação tumoral das células do CaP no tecido 
ósseo. Portanto, uma melhor compreensão dos mecanismos biológicos subjacentes ao papel 
da SPARC no CaP, deverá contribuir para uma melhor abordagem clínica e decisão 
terapêutica. Nesse sentido foi analisado o comportamento de diferentes culturas in vitro de 
linhas celulares do CaP, as quais, representam diferentes estados de carcinogénese prostática, 
no modelo 3D que mimetiza o osso e imobilizado com SPARC, nomeadamente em termos de 
morfologia, atividade metabólica e expressão dos níveis de SPARC. Pontos quânticos 
(Quantum Dots) foram funcionalizados diretamente com bioconjugados de SPARC-quitosano 
para atuarem como biomarcadores específicos para aplicação em imagiologia e identificação 
do processo de internalização por parte das células tumorais. Com base nos resultados obtidos 
verificou-se um comportamento celular distinto dependente do tipo de linha celular e da 
presença de SPARC exógena. Na verdade, a adição da proteína SPARC contribuiu para um 
aumento da taxa de sobrevivência e crescimento significativo num substrato que mimetiza o 
osso de uma linha celular (LNCaP) do CaP proveniente de metástases não ósseas. Além 
disso, a expressão da SPARC foi avaliada numa ampla série de amostras de tecido prostático 
desde amostras de tecido normal a amostras tumorais do CaP. Notavelmente, os níveis de 
expressão da SPARC foram mais elevados em doentes com índice de Gleason superior, 
equivalente a tumores indiferenciados com prognóstico reservado. Da mesma forma, os níveis 
vi 
de expressão desta proteína foram mais elevados em metástases em comparação com os 
seus respetivos tumores primários, especialmente as oriundas de tecido ósseo.  
Em resumo, obteve-se um biomaterial inovador constituído por nanofibras de colagénio e 
aglomerados de nanoHA através de co-electrospinning/electrospraying. Este material poderá 
ser utilizado em aplicações de engenharia de tecido ósseo, nomeadamente, na 
reconstrução/reparação de pequenos defeitos ósseos, ou como membrana funcionalizada, na 
regeneração do tecido ósseo e ainda no tratamento de outras doenças ósseas. Além disso, 
este biomaterial 3D semelhante ao osso funcionalizado com SPARC foi aplicado como modelo 
in vitro para estudar a importância da SPARC na carcinogénese da próstata e na metastização 
óssea. Este trabalho sugere um papel potencial da SPARC como um alvo clínico no CaP, por 
estar associado com a metastização óssea. 
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CHAPTER I 
 
Aim and structure of the thesis 
 
 
The increase of life expectancy in contemporary societies raises a growing socioeconomic 
concern in treating diseases associated to ageing like osteoporotic bone loss, bone infections 
as well as malignant tumors. In that sense, it is crucial to design biomaterials as similar to 
natural extracellular matrices (ECM’s) as possible and capable of being functionalized with 
active agents (molecules, growth factors or proteins) to enhance cell response in regeneration 
and reconstruction of bone tissue and in delivering target molecules for metastatic bone tumors 
treatment. In fact, the composites based on collagen and calcium phosphate are ideal for 
applications in tissue engineering and regenerative medicine since they mimic bone ECM 
components, namely the inorganic (calcium phosphate) and the organic component assembly 
made of collagen nanofibers.  
Electrospinning has recently attracted great interest in generating structures constituted by 
fibers with diameters ranging from a few microns to less than 100 nm, [1, 2] much smaller than 
those reported by other conventional methods. Until now, all collagen–HA composites obtained 
by electrospinning and described in the literature were prepared from a mixture of collagen and 
hydroxyapatite (HA) being the resulting composite surface covered with undifferentiated 
collagen or HA, preventing direct cell/protein contact individually, with both organic and 
inorganic components. [3-6] Moreover, natural polymers, including collagen, are very difficult to 
electrospin due to their high viscosity and low solubility in general organic solvents. To 
overcome this problem, most published works concerning the production of collagen fibrillar 
meshes uses organic toxic reagents such as 1,1,1,3,3,3- hexafluoro-2-propanol (HFP) that, 
apart from inducing toxicity, partially denatures the native structure of collagen. It is also 
common practice the addition of synthetic polymers such as polycaprolactone to collagen 
solution which when degraded, can release harmful compounds inducing serious clinical 
problems. [7-10] 
Based on the above-mentioned concerns an innovative biocomposite was developed meeting 
the currently required needs. This bone-mimetic construct was successfully obtained by 
simultaneous type I collagen electrospinning and nanophased hydroxyapatite electrospraying, 
using non-denaturating conditions and non-toxic reagents. Its topographic features reflect a 
mesh of collagen nanofibers embedded with crystals of HA, with fiber diameters within the 
nanometer range (30 nm), thus significantly lower than those reported in the literature, typically 
over 200 nm. Moreover this unique network architecture allows access to both organic and 
inorganic components, resembling bone tissue ECM organization.  
Chapter I 
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This bone-like biomaterial can also be used as a model or substrate for in vitro and in vivo 
scientific experiments to understand the mechanisms associated beyond tissue ageing or 
metastatic dissemination capacity of prostate and several other cancer cells into bone tissue. Its 
topographic and chemical features allow connecting points to be established with proteins, such 
as SPARC (secreted protein, acidic and rich in cysteine) also named “osteonectin”, a 
matricellular glycoprotein associated with tissue remodeling, repair, development, cell turnover, 
bone mineralization and growth and progression of tumors, namely cancer-related bone 
metastasis. [11-19] The disclosure of SPARC’s specific activity in mechanisms that occur in 
tumorigenesis and bone tissue metastasis may lead to the development of anti-angiogenic, anti-
proliferative or counter-adhesive therapeutic treatment against metastatic bone tumors. Indeed 
another goal of this thesis is the disclosure of SPARC’s role in prostate cancer bone metastasis. 
One of the followed strategies was precisely to mimic the tumor microenvironment found in 
bone metastasis. To achieve this, the previous referred bone mimetic biomaterial was grafted 
with SPARC to monitor in vitro its specific biological activity on prostate cancer cell cultures. 
 
 
This thesis was organized into five chapters and one appendix. 
 
Chapter I comprises the aim and structure of the present PhD thesis. 
 
Chapter II is divided in two parts. The first part gives an overview of bone tissue engineering, 
focusing on bone tissue and its architecture, functionality and important processes related to 
bone such as mineralization or bone remodelling. Bone mimetic materials are also succinctly 
reviewed, namely biomaterials presenting nanostructured hydroxyapatite and collagen, as well 
as electrospinning and electrospraying techniques used for their production. One particular 
application of these biomaterials as in vitro bone metastasis model is defined. 
In the second part of this chapter the role of SPARC in bone remodelling and cancer‐related 
bone metastasis is revised in detail by the author Nilza Ribeiro and advised by Rolf Brekken, a 
worldwide expert concerning SPARC.  
 
In Chapter III, the research on the production and characterization of a novel biocomposite that 
mimics the natural bone extracellular matrix is presented. Also, its influence on MC3T3-E1 
osteoblast cell performance in terms of morphology, adhesion and metabolic activity was 
investigated. This bone-like biomaterial based on collagen nanofibers and nanoHA 
agglomerates was designed using co-electrospinning/electrospraying. The collagen integrity as 
well as the nanoscale dimensions of both biocomposite components (collagen and nanoHA) 
were preserved as confirmed by FT-IR spectra, SEM and AFM image analysis. This novel 
construct allows cells access to both collagen nanofibers and HA crystals, as it happens in the 
natural bone environment. MC3T3-E1 behavior in 3D scaffolds revealed that these structures 
were cytocompatible and able to support osteoblast cell adhesion. The inclusion of nanoHA 
Aim and structure of the thesis 
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agglomerates by electrospraying in the network of type I collagen nanofibers improved the 
adhesion and metabolic activity of MC3T3-E1 osteoblasts. This new nanostructured collagen–
nanoHA composite holds great potential for healing bone defects or as a functional membrane 
for guided bone tissue regeneration and in treating bone diseases. This chapter includes the 
results of original research by the author Nilza Ribeiro. All the experimental work presented in 
this chapter was planned and executed by Nilza Ribeiro, with the exception of confocal imaging, 
which was technically assisted by Maria Gómez Lázaro. Also, SEM and AFM image processing 
and analysis were performed by CEMUP (Materials Center of the University of Porto) 
technicians. 
 
In Chapter IV, the influence of SPARC in prostate carcinogenesis and bone metastization was 
studied. This was explored assessing the morphology, metabolic activity and SPARC 
expression of different prostate cancer (PCa) cell lines resembling different stages of 
carcinogenesis, using the biocomposite described in chapter III as a bone biomimetic in vitro 
model grafted with SPARC. Furthermore, quantum dots directly functionalized by chitosan-
SPARC bioconjugates were used aiming at bioimaging and internalization towards tumor cells. 
Distinct cellular behavior was found, depending on PCa cell line type and presence of 
exogenous SPARC. Namely, SPARC addition contributed to the survival and significant growth 
of a non-bone metastatic PCa cell line (LNCaP) on bone-like construct. Moreover, SPARC 
expression was evaluated in an extensive series of prostatic tissue samples. SPARC was 
overexpressed in patients with higher Gleason Score, indicating tumors with poor prognosis, as 
well as in metastasis when compared with their corresponding primary tumors. These results 
indicate that SPARC is involved in the later stages of prostate cancer progression and therefore 
related to metastasis, and therefore support SPARC potential role as a clinical target on PCa. 
The present chapter focuses the scientific topic raised in second part of Introduction and 
collects expertise in two main areas, tissue engineering and cancer microenvironment. The 
materials production, following by immobilization of SPARC, plus the in vitro tests associated to 
SPARC expression analysis, using cell cultures and the 3D bone biomimetic model were 
executed by Nilza Ribeiro. SPARC expression analysis from prostate clinical samples and from 
prostate cell lines cultured in wild-type conditions were carried out by the co-author Pedro 
Costa-Pinheiro, under the scope of a collaboration with IPO-Porto. Nilza Ribeiro and Marisa 
Pereira worked in flow cytometry analysis. Maria Gómez Lázaro technically assisted in confocal 
imaging. This work also includes the collaboration of Prof. Herman Mansur and Prof. Alexandra 
Mansur in functionalization of SPARC with quantum dots (QD). 
 
Finally, Chapter V provides the general discussion and conclusions regarding the sum-up of the 
results obtained during this PhD project, as well as some perspectives and proposals for future 
work. 
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The Appendix contains the PCT Application WO2015/162559 A1 entitled “mesh composition 
for repairing or the regeneration of tissues and methods thereof”, which resulted from the work 
presented in chapter III.  
Aim and structure of the thesis 
 
 
5 
 
References  
[1] Bhardwaj N, Kundu SC. Electrospinning: a fascinating fiber fabrication technique. Biotechnol 
Adv 2010;28:325-47. 
[2] Shi JJ, Votruba AR, Farokhzad OC, Langer R. Nanotechnology in Drug Delivery and Tissue 
Engineering: From Discovery to Applications. Nano Lett 2010;10:3223-30. 
[3] Hild N, Schneider OD, Mohn D, Luechinger NA, Koehler FM, Hofmann S, et al. Two-layer 
membranes of calcium phosphate/collagen/PLGA nanofibres: in vitro biomineralisation and 
osteogenic differentiation of human mesenchymal stem cells. Nanoscale 2011;3:401-9. 
[4] Song W, Markel DC, Wang SX, Shi T, Mao GZ, Ren WP. Electrospun polyvinyl alcohol-
collagen-hydroxyapatite nanofibers: a biomimetic extracellular matrix for osteoblastic cells. 
Nanotechnology 2012;23. 
[5] Teng SH, Lee EJ, Wang P, Kim HE. Collagen/hydroxyapatite composite nanofibers by 
electrospinning. Mater Lett 2008;62:3055-8. 
[6] Venugopal J, Low S, Choon AT, Kumar TSS, Ramakrishna S. Mineralization of osteoblasts 
with electrospun collagen/hydroxyapatite nanofibers. J Mater Sci-Mater M 2008;19:2039-46. 
[7] Anderson JM, Rodriguez A, Chang DT. Foreign body reaction to biomaterials. Semin 
Immunol 2008;20:86-100. 
[8] Choi JS, Lee SJ, Christ GJ, Atala A, Yoo JJ. The influence of electrospun aligned 
poly(epsilon-caprolactone)/collagen nanofiber meshes on the formation of self-aligned skeletal 
muscle myotubes. Biomaterials 2008;29:2899-906. 
[9] Dawes E, Rushton N. The effects of lactic acid on PGE2 production by macrophages and 
human synovial fibroblasts: a possible explanation for problems associated with the degradation 
of poly(lactide) implants? Clin Mater 1994;17:157-63. 
[10] Wang GL, Hu XD, Lin W, Dong CC, Wu H. Electrospun PLGA-silk fibroin-collagen 
nanofibrous scaffolds for nerve tissue engineering. In Vitro Cell Dev-An 2011;47:234-40. 
[11] Bradshaw AD, Puolakkainen P, Dasgupta J, Davidson JM, Wight TN, Sage EH. SPARC-
null mice display abnormalities in the dermis characterized by decreased collagen fibril diameter 
and reduced tensile strength. Journal of Investigative Dermatology 2003;120:949-55. 
[12] Brekken RA, Sage EH. SPARC, a matricellular protein: at the crossroads of cell-matrix. 
Matrix Biology 2000;19:569-80. 
[13] De S, Chen JH, Narizhneva NV, Heston W, Brainard J, Sage EH, et al. Molecular pathway 
for cancer metastasis to bone. J Biol Chem 2003;278:39044-50. 
[14] Doi Y, Okuda R, Takezawa Y, Shibata S, Moriwaki Y, Wakamatsu N, et al. Osteonectin 
inhibiting denovo formation of apatite in the presence of collagen. Calcified Tissue International 
1989;44:200-8. 
[15] Donahue HJ. Summary--bone metastasis. Journal of musculoskeletal & neuronal 
interactions 2004;4:381-2. 
[16] Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell 
migration and invasion: A possible mechanism for metastasis to bone. Cancer Research 
1999;59:4453-7. 
Chapter I 
 
 
6 
 
[17] Ribeiro N, Sousa SR, Brekken RA, Monteiro FJ. Role of SPARC in Bone Remodeling and 
Cancer-Related Bone Metastasis. J Cell Biochem 2014;115:17-26. 
[18] Termine JD, Kleinman HK, Whitson SW, Conn KM, McGarvey ML, Martin GR. Osteonectin, 
a bone-specific protein linking mineral to collagen. Cell 1981;26:99-105. 
[19] Morrissey MA, Jayadev R, Miley GR, Blebea CA, Chi Q, Ihara S, et al. SPARC Promotes 
Cell Invasion In Vivo by Decreasing Type IV Collagen Levels in the Basement Membrane. PLoS 
Genet 2016;12:e1005905. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  7 
 
 
CHAPTER II 
 
Introduction 
 
 
1 – Bone tissue engineering  
 
 
1.1 - Bone function and structure 
Bone is a living conjunctive tissue composed by cells dispersed in bone matrix which contains 
both organic and inorganic components. Bone cells lie on and in a matrix. By wet weight, bone 
tissue is 70 percent mineralized matrix, 25 percent organic matrix and cells, and 5 percent 
water. All hard tissues of the human body contain calcium phosphates, except for small inner 
portions of the inner ear (cartilage). Calcium phosphates occur mainly in the form of poorly 
crystallized non-stoichiometric Na-, Mg-, and carbonate-containing hydroxyapatite (biological 
apatite). Hydroxyapatite (HA), Ca5(PO4)3(OH), usually written as Ca10(PO4)6(OH)2 since the 
crystal unit cell comprises two molecules, has in its structure individual crystals with a plate-like 
morphology, 15-200 nm nm long and 10-80 nm wide with a thickness between 2 and 7 nm. [1] 
The relative ratio of calcium to phosphorus ratio may vary markedly under different nutritional 
conditions, the Ca/P ratio on a weight basis varying between 1.3 and 2.0. For stoichiometric HA 
this ratio has the value of 1.667. The HA crystals of the mineral part are bound to collagen fibers 
that correspond 90 to 95 percent of the organic matrix of bone. The mineral phase is also 
responsible for withstanding mechanical stress under compression, while collagen provides 
tensile properties. The rest of the organic component is made up of noncollagenous proteins, 
proteoglycans, osteonectin, sialoproteins, osteocalcin, and bone morphogenic proteins (BMPs) 
that influence matrix organization, mineralization, and bone cell behavior. Structurally, the 
organic matrix is responsible for withstanding deformation under tensile stresses: when bone 
possesses inadequate or abnormal collagen, as in the case of osteogenesis imperfecta, it 
becomes especially brittle and easily fractured. The organic matrix also contains enzymes, 
hormones and growth factors that most likely play a part in bone cell regulation. Together, the 
organic and inorganic matrix of bone forms a material that is both very durable and stable. The 
remaining portion of the organic matrix is a homogeneous medium called ground substance. 
The ground substance is composed of extracellular fluid of proteoglycans, especially 
chrondroitin sulfate and hyaluronic acid. Bone tissue functions include support, protection and it 
also provides the transformation of skeletal muscles contractions in useful movements.  
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Bones can act as reservoirs for ions, especially for calcium and phosphate, playing an important 
role in calcium metabolism. Only 0.1% of the total calcium is in blood and extracellular fluid 
(Table 1). [2] This calcium pool is in a rapidly exchanging equilibrium with large calcium pools 
being controlled by three organs (bone, intestine, and kidney), each of which is an important site 
for the regulation of mineral metabolism. The marrow, located within the medullar cavity of long 
bones and interstices of cancellous bone, produces blood cells and stem cells in a process 
called haematopoiesis. 
 
Table 1 - Distribution of calcium, magnesium, and phosphate in the body of a 70-kg adult* [2] 
Compartment Calcium (g) Magnesium (g) Phosphate (g) 
Bones and teeth 1300 (99) 14.0 (54) 600.0 (86) 
Extracellular fluid 1 (0.1) 0.3 (1) 0.2 (0.03) 
Cells 7 (1.0) 12.0 (46) 100.0 (14) 
Notes: *Most of calcium is in bone and almost half of magnesium is in cells. Phosphate, as the 
principal counter ion to calcium and magnesium, has an intermediate proportional distribution. 
Number in parentheses is the percentage of total content for that mineral. 
 
 
Bones are usually classified in terms of shape as long, short, flat, irregular, sesamoid or 
accessory. The shapes of bones are generally related to their mechanical roles, namely those 
involving the support or movement of body parts. The long bones provide an excellent model for 
the gross anatomy of a typical bone. Most adult long bones have a tubular shaft called the 
diaphysis, which is a hollow cylinder with walls of compact bone tissue. The center of the 
cylinder is a medullary cavity, which is filled with marrow. At each end of the bone there is a 
roughly spherical epiphysis of spongy bone tissue. Separating these two main sections at either 
end of the bone is the metaphysic. It is made up of the epiphyseal (growth) plate and the 
adjacent bony trabeculae (latticework) of spongy bone tissue on the diaphyseal side of the long 
bone. The epiphyseal plate is a thick plate of hyaline cartilage that provides the framework for 
the synthesis of the cancellous bone tissue within metaphysis. The epiphyseal plates are the 
only places where long bones continue to grow in length after birth. The medullary cavity 
running through the length of the diaphysis contains yellow marrow, which is mostly fat (adipose 
tissue). The porous network of the spongy epiphyses is filled with red bone marrow (myeloid 
tissue). The red bone marrow produces primarily red blood cells that give the marrow its color. 
The thin membrane lining the medullary cavity of compact bone tissue and covering the 
trabeculae of spongy bone tissue is the endosteum. Covering the outer surface of the bone is 
the periosteum, a fibrous membrane that has the potential to form bone during growth periods, 
and in fracture healing. The periosteum is often attached to the underlying bone by collagenous 
fibers called periosteal performing (Sharpey’s) fibers. The periosteum contains nerves, 
lymphatic vessels, and many capillaries that provide nutrients to the bone and give placed by 
articular cartilage, which provides a slick surface that reduces friction and allows the joint to 
work smoothly.  
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Essentially, all bone tissue can adopt one of two macroscopic organizations, trabecular or 
compact (Fig. 1 [A]), whether mature, growing, pathologic, or healing. [3] The compact bone 
tissue also termed cortical or lamellar bone, which is predominant in the outer shell of bones, is 
characterized by little metabolic activity and few cells. 
It has a highly organized extracellular matrix of mineral and parallel bundles of type I collagen. It 
contains roughly cylindrical units of calcified bone known as osteons or Haversian systems. 
 
 
Fig. 1 – [A] An enlarged longitudinal section of compact bone tissue showing blood vessels, canals, and 
other internal structures. [B] An enlargement of a single osteon with lacunae, canaliculi, and a central 
(Haversian) canal visible. [C] An enlarged osteocyte inside a lacuna. [3] 
 
 
These cylinders are made up of concentric layers, or lamellae of bone. The structure of osteons 
provides the great strength needed to withstand typical, compressive forces on long bones. In 
the center of osteons are central canals (Haversian canals), longitudinal channels that contain 
blood vessels, nerves, and lymphatic vessels (Fig. 1 [B]). [3] Central vessels usually have 
branches called perforating canals (Volkmann’s canals) that run at right angles to the central 
canals and extend the system of nerves and vessels outward to the periosteum and inward to 
the endosteum of the bony marrow cavity. Lamellae contain lacunae that house the osteocytes, 
or bone cells. Radiating like spokes from each lacuna are tiny canaliculi that contain the slender 
extensions of the osteocytes. Nutrients and waste products can pass to and from the blood 
vessels in the central canals by normal processes of intracellular transport within each 
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osteocyte, over gap junctions from one osteocyte to another, or possibly via tissue fluid in the 
tiny spaces between the osteocytes and their surrounding lacunae (Fig. 1 [C]). [3]  
During embryonic development or in states with pathologic increase of bone turnover, bone 
assumes a less organized “woven” architecture and becomes hypercellular. Within the 
epiphyseal and metaphyseal regions of long bones as well as throughout the interior of short 
bones, bone is organized as a series of thin, interdigitating plates; this is termed trabecular, 
cancellous (lattice-like), or spongy bone. Its surface to volume ratio is higher than that found in 
cortical bone and is thus better suited to rapid turnover.  
Whilst all bone consist of cells embedded in an amorphous and fibrous organic matrix 
permeated by inorganic bone salts, its fine structure varies widely with age, site and history of 
the tissue. The various longitudinal and radial zones of a long bone have distinctive 
developmental histories and structures, and have been given regional names. For all these 
reasons, a large and initially often rather confusing terminology has been describing bony 
tissue. For clarification, the commonly used terms have been grouped as a Table 2. [4] 
 
 
1.2 - Bone cells 
Bones contain four types of cells capable of providing essential physiologic activities, including 
bone modeling and remodeling, facture healing, and mineral homeostasis. Yet this active cell 
population derived from two distinct cellular lineages. Osteoblasts, bone lining cells, and 
osteocytes are derived from cells with high mitotic potential, the multipotential primitive 
mesenchymal cells. On the other hand hematopoietic monocyte-macrophages can be 
transformed into osteoclasts.  
 
 
1.2.1 Osteoblasts 
Osteoblasts are usually found in the growing portions of bones, including periosteum, and are 
responsible for the synthesis of osteoid, the nonmineralized portion of the bone matrix. The 
progression from mesenchymal progenitor cells to pre-osteoblasts is marked by migration, 
proliferation, and differentiation of the cells, with a concomitant change in appearance from thin 
and flat to plump, eosinophilic, and cuboidal, such events are inducible by cytokines. Then there 
is differentiation into a full-fledged osteoblast that lasts 2 to 3 days and is highlighted by 
formation of a contiguous layer of cells and increased alkaline phosphatase levels. Osteoblasts 
manufacture several products, hormones, such as prostaglandins, proteins such pro-α1 
collagen, that constitutes the majority of osteoid, osteocalcin and bone morphogenetic proteins 
are other notable products, to act on the bone itself. They robustly produce alkaline 
phosphatase, an enzyme that has a role in the mineralization of bone, as well as many matrix 
proteins. During this process of mineralization calcium salts are deposited in the fibrous osteoid, 
and the osteoid is calcified into bone matrix. Osteoblasts act as pump cells to move calcium and 
phosphate into and out of bone tissue. An individual osteoblast can produce 0.5 to 1.5 µm/day 
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of an osteoid seam for approximately 8 weeks. Osteoblasts have an extensive endoplasmic 
reticulum with multiple cisternae, well-developed Golgi bodies, and numerous ribosomes, which 
all point to its massive synthetic efforts. Also they are connected by numerous gap junctions, 9 
nm in size, which facilitate communication between cells via chemical or electrical signals. 
Osteoblasts follow one of three fates: cell death (apoptosis), differentiation into a bone lining 
cell, or differentiation into osteocytes surrounded by matrix. 
 
Table 2 – Terminology applied in bone tissue description. [4] 
1. Macroscopic appearance of cut surface 
- Compact bone (cortical or lamellar bone) - The ivory-like surface layers of mature bone.  
- Trabecular bone (cancellous or spongy bone) - The interior of mature bones.  
2. Development origin 
- Intramembranous (mesenchymal or dermal bone) - from direct transformation of condensed 
mesenchyme. 
- Intracartilaginous (cartilage or endochondral bone) - replacing a preformed cartilage model. 
3. Regions of long bones 
- Diaphysis - central region of shaft. 
- Metaphysis - more recently developed ends of shaft. 
- Epiphysis - the bone ends with a separate centre of ossification. 
4. Organization of collagen fibres 
- Woven-fibred bone (coarse-bundled bone), with an irregular collagen network; includes embryonic bone; 
isolated patches in adult; formed during fracture repair. 
- Parallel-fibred bone - this includes all forms of lamellar bone and non-lamellar primary osteons. 
5. General microstructure 
- Non-lamellar bone - includes early woven-fibred bone and primary osteons. 
- Lamellar bone - almost all mature bone. 
6. Disposition of lamellae 
- Circumferential lamellae (primary lamellae) - parallel to both periosteal and endosteal bone surfaces. 
- Osteonic lamellae (secondary lamellae) - concentric lamellae around the vascular canals of mature bone. 
- Interstitial lamellae - in the crevices between osteons. 
7. Types of osteon 
- Primary osteons (atypical Haversian systems) - the first formed non-lamellar osteons. 
- Secondary osteons (typical Haversian systems) - concentric lamellae around the vascular canals of 
mature bone. 
8. General terms 
- Surface bone - usually circumferential lamellae but may include woven-fibred areas. 
- Interstitial bone - found between osteons; often the lamellar remnants of secondary osteons but may 
include woven-fibred or primary osteon fragments. 
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1.2.2 Bone lining cells 
Bone lining cells are lined on bone surfaces, including endosteal, periosteal, and intracortical 
surfaces. These cells are differentiated from osteoblasts that cease their physiologic activity. 
Bone lining cells have a flattened appearance with cytoplasmic extensions into the bone to 
contact osteocytes. Their main function is to serve as an ion barrier that mediates bone 
resorption, site activation and preparation, mononuclear recruitment, capillary budding, and 
attraction of pre-osteoclasts. Initiation of resorption by parathyroid hormone (PTH), 1,25-
dihydroxycholecalciferol (vitamin D), or prostaglandins leads to decreased synthesis of collagen 
and alkaline phosphatase. It also increases production of cyclic adenosine monophosphate 
(cAMP), which causes the cell to become more rounded, exposing the bone surface to 
osteoclastic activity. Collagenase secretion dissolves the endosteal membrane, contributing to 
the exposure of the bone surface. Indirectly, the bone lining cell also activates osteoclasts and 
inhibits osteoblastic anabolic activity.  
 
 
1.2.3 Osteocytes  
Osteocytes are the main cellular component of bony tissue, making up 90 percent of all bone 
cells. These cells are originated from osteoblasts that become trapped by osteoid produced 
around them. Each osteocyte is a single mononuclear cell body that occupies a lacuna within 
bone matrix and has long cytoplasmic processes that extend through the matrix, forming a large 
canalicular system. This system essentially constitutes a three-dimensional array or 
“syncytium”, extending beyond osteonal limits, which is ideal for chemical, electrical, and stress-
generated fluid communication. Osteocytes communicate with osteoblasts and bone lining cells, 
as well as other osteocytes. The connections are made up of gap junctions formed by six 
identical membrane-protein subunits termed connexins. Osteocytes along with osteoclasts play 
an active role in calcium homeostasis by helping to released calcium from bone tissue into the 
blood, thereby regulating the concentration of calcium in the body fluids. It has been proposed 
that osteocytes have another role in the communication of biophysical signals between cells 
within and at the surface of the bones. Indeed they may sense mechanical deformations pick up 
directly the electric potentials produced by the flow of ions across the negatively charged bone 
surface. Interestingly, the extent of the osteocytes syncytium slowly diminishes with age, 
decreasing its sensitivity to biophysical signals. 
 
 
1.2.4 Osteoclasts 
Osteoclasts are the cell responsible for bone resorption and as such constitute the 
counterweight to osteoblasts. In contrast to osteoblasts, osteoclasts are multinucleated and 
motile, capable of traveling 100 µm in a day. As it moves, the osteoclast will resorb bone in a 
300-µm-diameter tunnel, excavating up to 200,000 µm
3
 each day. The development and 
activation of osteoclasts include hormones such as 1,25(OH)2D3, PTH, and tumor necrosis 
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factor (TNF) that are mediated by osteoblasts cell products. The combination of these factors 
induces the production of calcitonin receptors, the expression of carbonic anhydrase, and 
intense tartrate-resistant alkaline phosphatase (TRAP) activity. Osteoclast functionality is made 
possible by several ultrastructural modifications that enable the cell to move about on bone 
surfaces, and resorbs (dissolving and assimilating) first the mineral component, and then the 
remaining organic matrix from sites where it is either deteriorating or not needed. Before the 
process of bone resorption can occur, the osteoclast must recognize and adhere to the bone 
surface in question, forming a resorption compartment. This is mediated via integrin found in 
vitronectin, a bone matrix molecule (blocking the integrin activity prevents osteoclastic bone 
resorption). Then osteoclasts are able to secrete hydrogen ions, colagenases, and hydrolases 
(derived from lysosomes). Numerous vacuolar proton-ATPase pumps then localize to the ruffled 
border and, in concert with the intracellular carbonic anydrase II, lower the pH of the 
extracellular bone compartment, which forms a resorption pit. This metabolic activity is 
supported by numerous pleiomorphic mitochondria. At physiologic pH (7.4) hydroxyapatite is 
essential insoluble; lowering the pH allows the pericellular concentration of Ca
2+
 to increase 10- 
to 20-fold up to 40 mM. [5] Lysosomal enzymes –for example, cathepsin B and acid proteases 
then digest the exposed organic matrix, completing the dissolution of bone. 
 
 
1.3 The Histogenesis of bone 
Bones such as those in roof and sides of the skull are preceded by fibrous membrane, whereas 
shaped rods or masses of cartilage precede the majority of bones. Hence, bones can develop in 
the embryo in two ways of ossification (osteogenesis): intramembranous ossification or 
intracartilaginous ossification. However, there is no essential difference between these two 
methods of bone formation. Bone is the same, only the bone-making sequence is different. 
 
 
1.3.1 Intramembranous (Mesenchymal) ossification  
The intramembranous ossification is developed in bone tissue (spongy or compact) and it is 
essentially the direct mineralization of a highly vascular mesenchymal (embryonic connective) 
tissue. Fig. 2 describes this process of ossification in the skull. [3] This process commences at 
certain constant points known as centers of ossification. The mesenchymal cells 
(osteoprogenitor cells) become larger and more numerous, and their processes thicken and 
connect with other embryonic connective tissue cells, forming a ring of cells around a blood 
vessel (Fig. 2 [B]). [3] Then mesenchymal cells differentiate into osteoblasts that secrete osteoid 
(Fig. 2 [C]). [3] The osteoblasts begin to cause calcium phosphate deposits that form the 
spongy, lattice like bone matrix. These deposits are later transformed into typical needle-shaped 
hydroxyapatite crystallites intimately related first to the cores of matrix vesicles, and 
subsequently to the collagen fibers of the matrix. As further layers of calcifying matrix are 
added, some osteoblasts become surrounding by matrix and are now included in lacunae within 
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the developing bone. The entrapped osteoblasts, now called osteocytes (Fig. 2 [D]), preserve 
the integrity of the matrix and also regulate the calcium homeostasis through their canaliculi 
system that facilitates the exchange of small molecules like parathyroid hormones. [3] While the 
osteoblasts are synthesizing and mineralizing the matrix, osteoclasts are playing a role in bone 
resorption by removing small areas of bone (calcium) from the walls surrounding the lacunae 
(Fig. 2 [E]). [3] Osteoclasts secrete a combination of acid medium and acid hydrolase enzymes 
(derived from lysosomes). The acid medium creates a low pH in which the enzymes disintegrate 
bone tissue. As the sequence of matrix secretion, calcification and entrapping of osteoblasts 
proceeds, the trabeculae gradually thicken and the intervening vascular spaces become 
progressively narrowed. Where the bone persists as cancellous bone, however, the process 
slows and the spaces later become occupied by haemopoietic tissue. In the regions where 
compact bone is formed, the process of trabecular thickening and vascular space narrowing 
continues. The osteoblasts on the surface of the spongy bone tissue form the periosteum. It is 
made up of an inner osteogenic layer (with osteoblasts) and a thick, fibrous outer layer. The 
inner layer eventually creates a protective layer of compact bone tissue over the interior 
cancellous tissue. Once intramembranous ossification has stopped, the osteogenic layer 
becomes inactive, at least temporarily. It becomes active again when necessary – to repair a 
bone fracture, for example. 
 
 
Fig. 2 – Intramembranous ossification. [A] The mesenchyme forms. [B] The mesenchymal cells enlarge 
and form a ring around a blood vessel. [C] The mesenchymal cells differentiate into osteoblasts that 
secrete osteoid. [D] As the ostoid calcifies into bone matrix, it entraps osteocytes in lacunae. [E] The 
osteoclasts remove small areas of bone (calcium) from the walls of the lacunae. [3]  
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1.3.2 Intracartilaginous (Endochondral) ossification 
This type of ossification involves replacing of a cartilaginous model and is best observed in long 
bones, such as the humerus or femur. Notice that the cartilage itself is not converted into bone, 
instead it is completely destroyed and replaced by newly formed bone. The events that occur in 
endochondral ossification at the cellular level can be seen in Fig. 3. [3] This process begins to 
take place on a cartilaginous matrix that includes chondrocytes (cartilage cells) in lacunae (Fig. 
3 [A]). [3] These cartilage cells secrete alkaline phosphatase, which causes mineralization 
(calcification) of the matrix into cartilaginous spicules (Fig. 3 [B]). [3] The calcified matrix blocks 
the diffusion of nutrients to the chondrocytes, which begin to die. Eventually they are resorbed, 
leaving irregular cavities in the ossifying matrix of trabeculae (Fig. 3 [C]). [3] Once bone is 
formed, these cavities contain the bone marrow. Pluripotent cells lining the cavities begin to 
differentiate into osteoblasts and osteocytes. The osteoblasts deposit osteoid on the 
mineralized cartilage cores, forming a thin layer of spongy bone tissue (Fig. 3 [D]). [3] 
Osteoclasts are involved in bone resorption during this stage of endochondral ossification. 
 
 
Fig. 3 – Early stages of endochondral ossification. [A] The chondrocytes and lacunae in the cartilaginous 
matrix. [B] As the chondrocytes and lacunae enlarge, the matrix begins to mineralize. [C] The 
chondrocytes die and are resorbed, leaving irregular cavities in the mineralized cartilage. [D] Bone cells 
develop from pluripotent cells lining the cavities. [3] 
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1.4 Mineralization 
Bone mineralization is the transformation of hydroxyapatite from a soluble form into a solid form, 
starting at multiple nucleation sites and then spreading by accretion within bone matrix. 
Mineralization occurs in two stages: primary mineralization, which is a rapid increase in mineral 
to about 70% of its final density due to nucleation and crystal multiplication, and secondary 
mineralization, which is a more gradual completion of mineralization due to crystal growth. [6] 
Initiation of mineralization occurs at multiple independent nucleation sites, separated by 640 
nm, that coincide with collagen hole zones. [7] The process of tissue mineralization continues 
by the decreasing free energy associated with increasing mineral accretion. [7] As the crystals 
expand, the collagen fibrils help to direct their alignment and orientation so that, in their final 
form, the crystals are aligned parallel with collagen. Other nucleation sites, besides, collagen 
hole zones, were found, namely osteoblastic mitochondria, and matrix vesicles, since they 
revealed the presence of calcium phosphate particles. Matrix vesicles develop as buds from 
hypertrophic chondrocytes or osteoplastic plasma membranes undergoing apoptosis. 
Nucleation within the vesicles occurs at the internal membrane and is mediated by membrane-
bound acidic phospholipids and a membrane-bound calcium pump. Mineralization in organic 
tissues represents a complex, dynamic, and site specific process that integrates the actions of 
multiple cells, enzymes, and other proteins including osteonectin, fibronectin, and 
phosphoproteins to create a structurally and biologically competent tissue. Moreover the 
regulation of this process relies largely on a substance called inorganic pyrophosphate, which 
inhibits abnormal calcification. Levels of this important bone regulator are controlled by at least 
three other molecules: nucleotide pyrophosphatase phosphodiesterase 1 (NPP1), which 
produces pyrophosphate outside the cells; ankylosis protein (ANK), which further contributes to 
the extracellular pool of pyrophosphate by transporting it from the cell interior to the cell surface; 
and tissue nonspecific alkaline phosphatase (TNAP), which breaks down pyrophosphate in the 
extracellular environment, keeping its levels in check. [8] Another player in the regulation of 
bone mineralization was identified, a protein called osteopontin. Its levels are highly correlated 
with pyrophosphate levels, but whether the two are acting in concert or if one controls the other, 
is still unknown. Conversely, there are molecules like proteoglycans that act as agents inhibiting 
mineralization. These agents bind to calcium ions, inhibit their diffusion, and exclude the 
inorganic phosphate necessary from continued mineralization. The high concentration of 
proteoglycans presented in ligaments, tendons, and skin may be responsible for the impediment 
of mineralization in these tissues. During the process of endochondral ossification, proteoglycan 
moieties gradually decrease in amount and size, thus decreasing the number of bound calcium 
ions. Some authors postulate a possible role for matrix vesicles, suggesting that they release 
enzymes that degrade proteoglycans, allowing mineralization to advance. [9] Collagen structure 
may also play a role in resisting mineralization by tightly packing collagen fibrils and severely 
hindering ion diffusion. [10] 
Two main sets of theories have been developed to explain the formation of HA crystals in 
biological tissues. [11] The first theory considered bone crystal formation as a continuous 
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mechanism which transforms a poorly crystalline phase into a crystalline HA phase. The second 
theory is based on the existence of a precursor mineral phase. The two most prominent 
precursors are octacalcium phosphate (OCP) and amorphous calcium phosphate (ACP). The 
nucleation process leading to the formation of ACP and the phase transformation from ACP to 
HA still remains to be clarified. 
An inaccurate mineralization process can result in too little mineral or too much mineral, being 
formed either of which can compromise bone health. Examples of pathologic states are rickets 
and osteomalacia which are characterized by adequate production of osteoblastic osteoid but 
insufficient mineralization. As the percentage of unmineralized matrix increases, the skeleton 
becomes subject to deformity and pathologic fracture. [7] 
 
 
1.5 Bone remodeling, healing and repair  
Bone is a dynamic tissue that includes the joint occurrence of chemical, cellular, biophysical, 
and hormonal processes that lead to a constant turnover. Modelling is strictly a process that 
increases the amount of bone tissue in the absence of resorption (e.g., periosteal surface 
apposition). Remodeling, on the other hand, changes bone morphology through the coordinated 
processes of bone formation and resorption (e.g., drilling and refilling of an osteon or cortical 
drift). The cycle of bone resorption and formation is a highly orchestrated process carried out by 
a multicellular units, called the basic multicellular units (BMU) or osteons, which comprising both 
osteoclasts and osteoblasts (Fig. 4). [12] 
 
 
Fig. 4 – Schematic representation of bone remodeling. The cycle of bone remodeling is carried out by 
basic multicellular units (BMU), comprising a group of osteoblasts and osteoclasts. In cortical bone, the 
BMUs tunnel through the tissue, whereas in cancellous bone, they move across the trabecular surface. 
The process of bone remodeling is initiated by contraction of the lining cells and the recruitment of 
osteoclast precursors. These precursors fuse to form multinucleated, active osteoclasts that mediate bone 
resorption. Osteoclasts adhere to bone and subsequently remove it by acidification and proteolytic 
digestion. As the BMU advances, osteoclasts leave the resorption site and osteoblasts move in to cover 
the excavated area and begin the process of new bone formation by secreting osteoid, which is eventually 
mineralized into new bone. After osteoid mineralization, osteoblasts flatten and form a layer of l ining cells 
over new bone. [12] 
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Bone modeling occurs initially within a membrane or along the edge of cartilage (e.g., 
periosteum or periphyseal growth plate). Alternatively the cortical bone is constantly going 
through slow and orderly cycles of localized resorption and rebuilding. Remodeling begins with 
osteoclasts digging a cavity; as the resorption front advances, other cells replace osteoclasts. 
Over an interval of several months, new bone is deposited in cylindrical lamellae around the rim 
of the cavity until it is refilled to complete this cycle. This is an important example of normal, 
coordinate relationship between bone resorption and bone formation processes. The 
determinants of this coupling between bone resorption and formation are not known, but they 
probably include growth factors present at high local concentrations in bone extracellular matrix 
and exposed or released during the skeletal resorption process. Bone morphogenetic proteins, 
(BMPs) and growth and differentiation factors, (GDFs) belong to a super family of proteins 
named as transforming growth factor super family (TGF-β) that share a similar biological 
activity. These polypeptides mediate a number of physiological processes such as immune 
response, regulation of hormone secretion, growth and cell differentiation, morphogenesis, the 
regeneration of tissues as well as the induction and remodeling of bone. 
Lesions in bones such as fractures or infections involve mechanisms of bone resorption and 
new bone formation but also the growth of new blood vessels into the involved area. In injuries 
that disrupt the organization of the tissue, such as a fracture in which apposition of fragments is 
poor or when motion exists at the fracture site, the progenitor stromal cells differentiate into cells 
with functional capacities different from those of osteoblasts, form varying amounts of fibrous 
tissue and cartilage. When there is good apposition with fixation and little motion at the fracture 
site, repair occurs predominantly by formation of new bone without other scar tissue. 
Remodeling of bone occurs along stress lines of force generated by mechanical effort. The 
signals from these mechanical stresses are sensed by osteocytes that transmit signals to 
osteoclasts or osteoblasts, or their precursors. A bowing deformity increases new bone 
formation at the concave surface and resorption at the convex surface, seemingly designed to 
produce the strongest mechanical structure. Expanding lesions in bone, such as tumors, induce 
resorption at the surface in contact with the tumor, by producing ligands, such as PTHrP 
(parathyroid hormone-related peptide), that stimulate osteoclast differentiation and activity. 
Even in a disorder as architecturally disruptive as Paget’s disease, remodeling is dictated by 
mechanical stresses. Thus, bone plasticity reflects the interaction of cells between each other 
and with the environment. [12] 
 
 
1.6 Bone mimetic Biomaterials 
In bone tissue engineering and regenerative medicine one of the main interests is to obtain 
adequate matrices or scaffolds that mimic the bone extracellular matrix, bounding to bone, and 
in some cases activating gene expression in osteoblast-like cells to stimulate new bone growth. 
[13] These adaptable biomaterials should be specifically designed to be biocompatible, 
biodegradable and osteoconductive. [14] Moreover they may be adjusted in terms of 
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composition and chemical stability, crystallinity, porosity and wettability or even be carriers of 
bioactive molecules, growth factors and/or living bone cells.  A wide range of materials have 
been studied for the development of synthetic bone scaffolds. They include metals and metallic 
alloys such as titanium, stainless steel, and cobalt-chromium, synthetic polymers as polyesters 
(e.g. poly(lactic acid) (PLA), polyglycolic acid (PGA), polycaprolactone (PCL) or polyethylene 
terephthalate (PET)), polydioxanone, poly (propylene fumarate) (PPF), poly(ethylene glycol) 
(PEG), poly(orthoesters), polyanhydrides, and polyurethanes or natural polymers such as 
collagen, glycosaminoglycans, fibrin, silk, and others unconventional marine biomaterials like 
coral, chitosan, sponge skeleton or alginate. Another class of materials for bone replacement is 
undoubtedly the class of calcium-phosphate ceramics being the most common: hydroxyapatite 
(HAp), Ca10(PO4)6(OH)2, tricalcium phosphate (TCP), Ca3(PO4)2, biphasic calcium phosphates 
(BCP), and phosphate bioglasses. [15] Also several composites materials were developed 
consisting of two or more material aforementioned.  
Nowadays, much effort is being devoted to produce nanostructured biomaterials similar to the 
nanoscale structure and properties found in native bone tissue. As opposed to conventional 
materials (macro and micro), nanomaterials have a significant effect on adsorbing surrounding 
biomolecules including proteins, lipids, small molecules, saccharides, and nucleic acids defining 
a new cell-material interface.  It is this interface that mediates subsequent cellular association 
and cellular response. Nanomaterials have distinct physicochemical properties (size, available 
surface area, wettability, charge, roughness, etc.) suitable to be tuned to achieve the desired 
biologic responses for application in bone tissue engineering. In general, nano-featured 
surfaces provide a higher surface area that affects protein adhesion properties and promotes 
cell adhesion, proliferation, and differentiation. Furthermore, it has been shown that these 
nanostructures surfaces promote mineralization and enhance in vitro osteogenesis. [16-20] The 
definition of nanomaterials refers to materials containing particles, in an unbound state or an 
aggregate or as an agglomerate and where, for 50 % or more of the particles in size distribution, 
one or more external dimensions is in the size range 1 nm - 100 nm, such as nanocrystals, 
nanospheres, and nanofibers.  
In this chapter, the main focus is to briefly review the biomaterials that are present in native 
bone structure (e.g. HA and collagen) with tissue engineering at the nanoscale.  
 
 
1.6.1 Nanostructured hydroxyapatite Biomaterials 
Calcium phosphate biomaterials have been widely used in dentistry and orthopedic applications 
in various physical forms: powders, granules, dense and porous blocks, injectable 
compositions, self-setting cements, coatings on metal implants, composites with polymers, etc. 
Despite their exceptional properties such as biocompatibility, bioactivity, biodegradability and 
osteoconductivity, they are not capable, as opposed to living tissues, to heal or restore the 
diseased tissues or organs by maintaining a blood supply, or modify their properties in response 
to environmental factors such as mechanical stress. Significant attempts have been made to 
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produce synthetic biomaterials that closely mimic the HA crystals present in bone tissue. For the 
synthetic HA preparation several techniques has been employed, including hydrothermal 
reactions, sol-gel synthesis, pyrolysis of aerosols and micro-emulsion, biomimetic process, and 
chemical precipitation. Chemical precipitation is the most used alternative for the preparation of 
fine HA powders. [13] HA has been used as coating on orthopedic (e.g., hip joint prosthesis), 
and dental implants, as cement or added to some toothpastes as gentle polishing agent instead 
of calcium carbonate due to the chemical similarities to bone and teeth mineral enamel. Indeed 
the advances of the biomedical applications of calcium phosphates include the development of 
bioactive materials. Bioceramics made of dense HA revealed to be a good example of bioactive 
material, which dissolves slightly and promotes the formation of a layer of biological apatite 
before interfacing directly with the tissue at the atomic level, establishing direct chemical bond 
with bone. Such implants provide good stabilization for materials that are subject to mechanical 
stresses. However, when developing such biomaterials for biomedical applications, it is very 
important to obtain a complete characterization to understand the biological interactions that 
occur at the bone tissue/material interface and to improve bone-forming biomaterials. Several 
studies have shown that structural characteristics, such as, specific surface area, pore volume 
or particle size of the synthetic biomaterials might influence their response in physiological 
environment, such as the biological apatite deposition and bone bounding. In particular, the 
properties of nanophased hydroxyapatite as compared to microphased ceramic (conventional 
ceramic), such as surface grain size, pore size and wettability may control protein interactions 
(like adsorption, conformation and bioactivity) and thus guide cellular responses (osteoblast 
adhesion and long term functionality expressed as proliferation, synthesis of alkaline 
phosphatase and deposition of calcium containing mineral). [21] Therefore the production of 
ceramics scaffolds for future applications in bone tissue engineering includes chemical and 
physical modifications such nanostructured and nanocrystalline materials made of HA, similar to 
the complex hierarchical structures of hard tissues (bone and teeth) and also modification of the 
materials surface using growth factors, living bone cells or proteins. [22] 
 
 
1.6.2 Hydroxyapatite/collagen Biocomposites  
Nanohydroxyapatite/collagen nanocomposites are ideal biomaterials for bone regeneration and 
target molecule delivery systems for the treatment of bone diseases. These types of 
biomaterials are suitable for bone contact and substitution, particularly novel natural polymer-
based composites reinforced with bioactive components, such as nanoHA. [21, 23-26] They 
represent the major inorganic and organic component assembly similarly to natural bone where 
the hydroxyapatite (HA) crystals of the mineral part are bound to collagen fibers, corresponding 
to 90 to 95 percent of the bone organic matrix. The mineral phase is responsible for 
withstanding mechanical compressive stress, while collagen provides tensile stress resistance 
properties.  
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Over the last few years, a variety of nanofabrication techniques has emerged including 
electrospinning, nanotemplating, [27] electrostatic spray deposition, [28] RF plasma 
spray/deposition, [29] molecular self-assembly, [30, 31] and metal oxide anodization. [32, 33] 
Electrospinning has recently attracted great interest in generating nanoscale fiber of 
biomaterials ranging from polymers and ceramics to their composite fibrous scaffolds for tissue 
engineering applications with fiber diameter ranging from a few microns to less than 100 nm. 
[26, 34, 35] This type of nanofibrous structure is regarded as a promising architecture in the 
sense that the natural bone ECM exhibits collagen fibrils with diameters ranging from 20 nm to 
40 µm [36, 37] which are far thinner than those that can be achieved with conventional 
processing methods.   
In the present work a biocomposite based on type I collagen nanofibers and nanophased 
hydroxyapatite (nanoHA) was developed using the two techniques described below, namely, 
simultaneous electrospinning of type I collagen and electrospraying of nanoHA. 
Electrospinning occurs when a polymer solution is charged to high voltage to produce fibers. In 
this technique a polymer solution or melt is added to a capillary (which can be a syringe needle). 
Due to surface tension the solution forms a droplet at the tip of the needle. When a high electric 
voltage, between 5 and 30 kV, is applied to the solution electric charges accumulate in the 
droplet. When the electrostatic repulsion between the charges overcomes the surface tension 
and viscoelasticity of the droplet this assumes the shape of a cone. When the force exerted by 
the electric field, formed between the droplet and a grounded collector, overcomes the surface 
tension, a thin jet is formed. The jet of the charged solution is accelerated towards a grounded 
target under an electric field. If the solution is viscous enough to stabilize the jet, the polymer 
solution is severely stretched and the solvent evaporates to form ultrathin fibers that solidify and 
are deposited on the collector forming a non-woven mesh of fibers. A variant of electrospinning 
is electrospray. The basic difference between these two processes lies in the concentration of 
the solution. In electrospray the concentration is sufficiently low to destabilize the charged jet 
which then breaks down into small spherical droplets that solidify during the course and are 
deposited on the collector. In this case the polymer solution does not experience severe 
drawing and the formed film consists of small droplets instead of fibers. [38, 39]  
 
 
1.6.3 In vitro Bone metastasis model  
The combination of biomaterials and tissue culture techniques lead to recreation of in vitro 
engineering tumors for screening oncologic drugs and studying cancer biology. Indeed, the 
development of these in vitro models could be a valid strategy to understand the complex 
mechanisms that occur in tumorigenesis, angiogenesis, tumor invasion and metastasis in bone 
tissue. In recent years, both natural (e.g. basement membrane extract, type I collagen, alginate, 
chitosan, hyaluronic acid hydrogel) and synthetic materials (e.g. poly(lactic-co-glycolic acid) 
(PLGA) and Polyethylene glycol (PEG)), conventionally applied in engineering of nerve, bone, 
cartilage tissues have been used to create matrices and scaffolds for tumor engineering 
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purposes. [40-42] Nowadays, cellular microenvironment is recognized as holding an 
increasingly important role in tumor progression. In fact, a number of three-dimensional (3D) cell 
culture systems has been designed to study the impact of the tumor microenvironment on 
cancer cells, such as, matrigel, synthetic matrices, xenograft transplantation or rotary cell 
culture [40, 41, 43]. These 3D cultures models have the potential to overcome the limitations 
associated with two-dimensional (2D) monolayer cell culture platforms, as well as the 
complexities of in vivo animal models (xenografts) for improved understanding of cancer 
biology. It should be noted that, to date, 3D models regarding the study of cancer related bone 
metastasis, such as prostate cancer (PCa) are still lacking. Accordingly, a bone-biomimetic in 
vitro model is required to evaluate the behavior of PCa cells in the primary metastatic site. In 
this particular study, the biocomposite (collagen nanofibers/hydroxyapatite crystals) described 
later in Chapter III was applied as an in vitro model to help to recognize the potential role of a 
matricellular protein, osteonectin as a clinical target in prostate cancer, especially due to its 
association with metastatic dissemination ability of prostate cancer cells into bone. 
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Abstract 
There is a growing socioeconomic recognition that clinical bone diseases such as bone 
infections, bone tumors and osteoporotic bone loss mainly associated with ageing, are major 
issues in today’s society. SPARC (secreted protein, acidic and rich in cysteine), a matricellular 
glycoprotein, may be a promising therapeutic target for preventing or treating bone related 
diseases. In fact, SPARC is associated with tissue remodeling, repair, development, cell 
turnover, bone mineralization and may also participate in growth and progression of tumors, 
namely cancer-related bone metastasis. Yet, the function of SPARC in such biological 
processes is poorly understood and controversial. The main objective of this work is to review 
the current knowledge related to the activity of SPARC in bone remodeling, tumorigenesis and 
bone metastasis. Progress in understanding SPARC biology may provide novel strategies for 
bone regeneration and the development of anti-angiogenic, anti-proliferative or counter-
adhesive treatments specifically against bone metastasis. 
 
 
Key words: SPARC; bone remodeling; bone metastasis; tumorigenesis  
 
 
2.1 - Introduction  
SPARC (secreted protein, acidic and rich in cysteine), also termed osteonectin or BM-40, is a 
major bone matrix non-collagenous protein and a component of the extracellular matrix (ECM) 
of multiple tumor types. It is a member of a larger family of SPARC related proteins that 
modulate cell interaction with the extracellular milieu. [44] SPARC is in matricellular class of 
secreted glycoproteins that exhibit counter-adhesive effects that lead to cell developing round 
shape and other changes in cell morphology and disruption of cell-matrix interactions. [45] 
Journal of Cellular Biochemistry 115: 17-26 (2014). 
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Other members of the SPARC family include testican-1, -2 and –3, tsc 36 (transforming growth 
factor beta (TGF-β) stimulated clone 36), SPARC-like 1 also known as hevin/SC1 (synaptic cleft 
1), Mast9 or ECM2 and SPARC-related modular calcium binding (SMOC)-1 and -2. [46] 
SPARC, as a multifunctional calcium binding matricellular glycoprotein, participates in tissue 
remodeling, morphogenesis, and bone mineralization and is secreted by many different types of 
cells such as osteoblasts, fibroblasts, endothelial cells and platelets. [44, 47, 48] 
SPARC is a single-copy gene with a high degree of evolutionary conservation, with a molecular 
weight of 32.5 kDa that can be divided into three distinct modules as shown in Figure 5. 
Module I (NH2-terminal) contains immune dominant epitopes and binds to hydroxyapatite (HA). 
The NH2-terminal domain is an acidic region rich in asparagine (Asp) and glutamate (Glu) which 
can bind to 5-8 calcium ions, through a different mechanism found in a large family of calcium-
binding proteins, the helix-turn-helix structural domain (EF-hand motifs). It is also the region that 
is the most distinct from other members of the SPARC gene family. 
 
 
Fig. 5 - Structure of human SPARC protein. A ribbon diagram derived from crystallographic data shows 
the three modular domains of SPARC. The follistatin-like domain, aa 53-137 shown in red (except the 
peptide 2.1), aa 55-74 and the peptide 2.3 (amino acids 114–130) shown in green and black, respectively. 
Module III aa 138-286 is shown in blue (except the amino acids 255–274, peptide 4.2 shown in yellow). 
Adapted from Ref. [51] 
 
 
Module II, Cysteine-rich, is homologous to a repeated domain in follistatin (FS). It contains 
bioactive peptides that exert different effects on endothelial cells. Peptide 2.1 with an identical 
structure to epidermal growth factor (EGF)-like S hairpin, inhibits the proliferation of endothelial 
cells. Peptide FS-E, corresponds to EGF-like module in FS domain of SPARC. It potently 
inhibits endothelial cell migration in vitro and angiogenesis in vivo in a conformation-dependent 
manner. [49] Peptide FS-K has an inhibitory effect on endothelial proliferation. On the contrary, 
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peptide 2.3 has a stimulatory effect on endothelial cell proliferation and angiogenesis. [50] 
Additionally, the NH2-terminal region of module II may bind to heparin or to proteoglycans. [51] 
Module III binds to extracellular Ca
2+
 ions through EF-hand motifs. This module contains the 
peptide 4.2, which stimulates endothelial cells migration but inhibits their proliferation. [52] The 
fibril-forming collagen types I, III, and V, and the basement membrane collagen type IV, bind to 
module III in a Ca
2+
 dependent fashion. Cleavage of SPARC by matrix metalloproteinase 3 
(MMP-3) produces a peptide Z-1 containing a Cu
2+ 
binding sequence that exhibits a biphasic 
effect on endothelial cell proliferation and stimulates vascular growth. In contrast, peptides Z-2 
and Z-3 inhibit endothelial cells proliferation but stimulate their migration. Different regions of 
SPARC (designated peptides 1.1 - 4.2) are presented in Figure 6. 
 
 
Fig. 6 - The regions spanned by different SPARC peptides identified in various studies, adapted from Ref. 
[75] 
 
 
In vitro experiments provided evidence that SPARC:  
a) has a counter-adhesion effect on cells, since it disrupts cell adhesion to the ECM through its 
interaction with ECM components such as collagen and vitronectin; [53] 
b) promotes changes in cell morphology and cell differentiation; [53] 
c) inhibits cell cycle progression, namely by stalling cells in the G1 phase of cell cycle; [54-56] 
d) regulates the activity of growth factors, such as platelet-derived growth factor (PDGF), 
fibroblast growth factor (FGF) or vascular endothelial growth factor (VEGF); [52, 56] 
e) regulates ECM and matrix metalloprotease production; [54, 55] 
f) strongly binds to type I collagen and synthetic HA and mediates mineralization of the type I 
collagen; [44] 
g) inhibits adipogenesis and promotes osteoblastogenesis. [57] 
 
In addition to the described functions in vitro, SPARC-null mice are born with no obvious 
abnormalities, but shortly after birth these mice undergo progressive early-onset 
cataractogenesis. [58] Thus, the SPARC gene is required for lens transparency.  
Also SPARC-null mice exhibit an increased accumulation of white adipose tissue (WAT) and 
show osteopenia. This fact based on in vitro studies could be a consequence of the up-
regulation of catenin signaling and altered regulation of collagen expression and deposition. [57] 
Interestingly the overproduction of SPARC by the adipose tissue of obese mice contributes to 
increased plasminogen activator inhibitor 1 (PAI-1) levels in conditions associated with obesity. 
SPARC is highly related to body mass index as an autocrine and or/paracrine factor of the 
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adipose tissue that may affect key functions of this tissue and may influence bone metabolism. 
[59] 
Furthermore, SPARC controls important mechanisms involved in cancer development and 
progression. These include the regulation of the epithelial-to-mesenchymal transition (EMT), 
apoptosis, angiogenesis and also the regulation of the inflammatory response. These 
mechanisms are relevant in the metastatic dissemination capacity of several cancer cells into 
bone tissue. However the function of SPARC in such phenomena is contradictory. SPARC 
seems to be a key factor in biological processes such as bone remodeling, tumorigenesis and 
bone metastasis due to all the activities performed by this protein. (Figure 7)  
This review explores the correlation between SPARC expression/function in bone remodeling 
and in tumorigenesis, particularly in cancer-related bone metastasis. Ultimately, we aim to 
contribute towards filling a gap in the literature on the association of SPARC with bone 
metastasis and encourage further research and progress on novel strategies for bone 
regeneration and the development of anti-angiogenic, anti-proliferative or counter-adhesive 
treatments for metastatic bone tumors. 
 
 
2.2 - SPARC and bone remodeling 
Bone is a dynamic tissue that combines chemical, cellular, biophysical, and hormonal 
processes, which undergoes constant turnover. Modeling is a process that sculpts the shape 
and sizes of bone by the coordinated processes of bone formation and resorption. Modeling 
process is critical during growth but becomes relatively ineffective after skeleton maturity. 
Remodeling, on the other hand, is a process by which the skeleton is continuously renewed. It 
results in the turnover of lamellar bone without causing significant changes in bone quantity, 
geometry, or size. The purpose of remodeling is to adjust the skeleton to changes in mechanical 
demands, to prevent accumulation of fatigue damage, to repair micro fractures, to ensure the 
viability of the osteocytes, and to allow the skeleton to participate in the mineral homeostasis. 
[60] The bone resorption and formation cycle is a highly orchestrated process carried out by a 
multicellular unit, called the basic multicellular unit (BMU), which comprises osteoclasts and 
osteoblasts. [61] The determinants of the coupling between bone resorption and formation are 
not known, but they may include the expression pattern of growth factors and/or proteins that 
vary spatially and temporally. These polypeptides mediate a number of physiological processes 
such as immune response, regulation of hormone secretion, growth and cell differentiation, 
morphogenesis, the regeneration of tissues as well as the induction and remodeling of bone. 
[47] SPARC binds to ECM proteins such as types I, III, IV and V collagen, thrombospondin, 
PDGF-AB and PDGF-BB. SPARC binds strongly to type I collagen and synthetic HA and can 
mediate the in vitro mineralization of type I collagen. [44] It appears that SPARC has a role in 
connecting collagen fibers to HA crystals by a terminal sequence rich in amino acids. 
Attachment to collagen, however, has been reported both to promote and inhibit HA formation. 
[44, 62-64] 
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Fig. 7 - SPARC is a key protein in bone remodeling, tumorigenesis and bone metastasis and its activities 
associated to these biological processes are respectively indicated. 
 
 
Infrared analysis of the mineral and matrix in bones of SPARC-null mice revealed a decreased 
number of bone cells, leading to decreased bone formation and resorption, that could hinder the 
degradation and replacement of mature collagen, thereby maintaining collagen crosslinks. [65] 
Furthermore, a polyclonal anti-SPARC antibody did not affect on mineralization thus, as 
previously suggested, SPARC may be more important for regulating matrix formation than 
mineralization. [66] Crystal structure analysis and site-directed mutagenesis within module III 
revealed that five residues R149, N156, L242, M245, and E246 are required for collagen 
binding. In addition, SPARC recognized the hydrophobic GVMGFO motif in collagen. [67] The 
conformational change that occurred in SPARC during collagen binding created a deep 
specificity pocket that was bound to the phenylalanine side chain of the GVMGFO motif. Yet, 
the functional importance of these structural alterations is still not understood. On the other 
hand, post-translational modification of SPARC may be controlled in a tissue specific manner 
and potentially associated with functions of SPARC. Several reports indicated that SPARC 
participated in the regulation of collagen fibril assembly. [68, 69] More recently, it was shown 
that wild type matrices had thick collagen fibers organized into longitudinal bundles, whereas 
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SPARC-null matrices had thinner fibers in random networks. [70] Rentz et al., 2007, speculated 
that SPARC influenced procollagen processing by modulating integrin engagement and 
processes that affected collagen deposition and also improved matrix assembly. [71] The 
functional significance of SPARC interaction with collagens in tissues is not clear. Collagen may 
serve as a storage site for SPARC in the ECM or might directly modulate the activity of SPARC. 
Interestingly enough, bone and platelet SPARCs have patterns of glycosylation that appeared to 
affect collagen binding activity. Specifically, bone SPARC binds to types I, III and V collagen 
and platelet SPARC has no apparent affinity for them. [72]  
Some applications for SPARC have been explored in the development of advanced composite 
biomaterials for skeletal tissue regeneration. One example concerned the production of 
nanohydroxyapatite/collagen/SPARC composites for bone graft applications. [73] Others 
studies have used a glutamic acid-rich peptide derived from SPARC, functionalized with an 
acrylate group for covalent attachment to the matrix that significantly increased the shear 
modulus of a bone-mimetic hydrogel/apatite nanocomposite and improved the dispersion of 
apatite nanoparticles in aqueous solution. [74] 
 
 
2.3 - SPARC activity in cancer biology 
SPARC contributes to the disruption of cell adhesion to ECM by promoting morphologic 
changes in cell shape. SPARC also reduces the activity of several growth factors including 
PDGF, VEGF and bFGF. In addition, its ability to regulate matrix remodeling via 
metalloproteinases, together with its ability to inhibit G1 to S-phase cell cycle progression in 
primary cells, suggests that SPARC might participate directly in tumor progression suppression. 
[54, 55] SPARC involvement with different tumors is reported to be contextual and attributed to 
a given microenvironment. Different expression patterns and activities of SPARC are depending 
on cancer type and upon whether it is expressed by malignant cells themselves or by 
neighboring stromal cells. [75] 
SPARC expression is associated with a favorable prognosis in some studies on human prostate 
cancer. [76-78] In these studies SPARC may indeed function as a tumor suppressor since 
down-regulation and inactivation of SPARC gene expression enhanced aggressive and 
metastatic behavior. On the other hand, SPARC can be described as a protumorigenic and 
prometastatic protein as found in studies of colorectal cancer. [79] Moreover, high SPARC 
expression might have utility as a prognostic marker in human breast cancer. [80, 81] However 
SPARC has been associated with metastasis of prostate cancer, as high levels of SPARC were 
found at sites of bone metastasis. [82] Therefore the specific contribution of SPARC in tumor 
growth and progression is not clear. [83] Understanding of the mechanisms mediating SPARC’s 
functions in each different cancer-associated process may clarify how this complex 
multifunctional protein functions in cancer.  
One of the important mechanisms involved in cancer development and progression is 
apoptosis. In fact defects in apoptotic pathways are now thought to contribute to tumor initiation, 
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progression and metastasis. SPARC-mediated apoptosis occurs by activating the expression of 
several members of extrinsic pathways of apoptosis such as caspase 3, caspase 8, caspase 10 
and Fas-Associated protein with Death Domain (FADD). SPARC induced apoptosis in ovarian 
carcinoma cells and enhanced the chemosensitivity of colorectal cancer cells when exposed to 
chemotherapy either alone or in combination with vitamin D. [84-88] In contrast, the expression 
and activity of SPARC in human brain tumors promoted tumor invasion by reducing apoptosis 
and caspase activity of glioma cells through protein kinase B activation. [89-91]  
In tumorigenesis, an invasive and metastatic phenotype is often acquired via induction of an 
epithelial-mesenchymal transition (EMT) in which epithelial cells lose their polarity and develop 
a mesenchymal phenotype. This process is characterized by the loss of intercellular adhesion 
(E- to N cadherin switch), down-regulation of epithelial markers (cytokeratins), up-regulation of 
mesenchymal markers (vimentin) and the acquisition of a fibroblast-like motile and invasive 
phenotype. The transcription factor Snail and other members of its family have been implicated 
in the promotion of EMT. [92, 93] SPARC intervenes at several stages of EMT, thus contributing 
to malignant phenotype. For example, expression of SPARC in melanoma cells suppresses E-
cadherin and increases N- cadherin and vimentin expression through phosphorylation of focal 
adhesion kinase (FAK) and/or induction of Snail with the subsequent enhancement of cell 
migration and invasive capacity. [94-96] SPARC might be involved in a collagen-mediated EMT 
induction, since it induces collagen expression. [96-98] Moreover, SPARC was shown to 
modulate cell survival and invasion of glioma cells through the activation of FAK and Integrin-
linked kinase (ILK). [99]  
Another cancer-associated process is inflammation and SPARC likely plays a central role in this 
process, since its expression by malignant or stromal cells modulates the activity of growth 
factors and the capacity of inflammatory cells to infiltrate the tumor microenvironment. The 
suppression of SPARC expression in melanoma cells induced polymorphonuclear leukocyte 
(PMN) recruitment and inhibited tumor growth through a mechanism that involved the release of 
chemotactic factors such as interleukin 8 (IL-8) and leukotrienes by inflammatory cells. [100, 
101] 
SPARC has been implicated in angiogenesis, a process of neovascularization that is critical to 
the survival of tumors. In endothelial cells, SPARC is capable of inhibiting the activity of 
angiogenic growth factors VEGF, PDGF, and basic fibroblast growth factor (bFGF). [52] 
Furthermore, in animal models of ovarian cancer, the absence of SPARC resulted in high 
expression of VEGF, VEGFR2, MMP-2 and MMP-9, thereby promoting the angiogenic and 
metastatic potential of these cancers. [84, 102] In neuroblastomas SPARC can function as an 
antiangiogenic factor produced by Schwann cells being its expression inversely correlated with 
tumor progression. [57, 103] The role of SPARC in tumor angiogenesis is clearly dependent on 
the availability and activity of the intact protein, as well as its peptide fragments. For instance, 
peptides that include the KGHK-Cu
2+
 motif, stimulated endothelial cell cycle and angiogenesis in 
vivo. [104] On the contrary, FS-E peptide, inhibited angiogenesis associated with 
neuroblastoma, even in the presence of bFGF-stimulation. [49, 105]  
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2.4 - SPARC and cancer-related bone metastasis  
During tumor progression, malignant cells, initiate a process of attachment and subsequent 
degradation of nearby stroma, leading finally to the establishment of metastatic foci in specific 
tissues such as lung, bone, liver or brain. [106] This contributes to the success of the tumor and 
consequently to poorer prognosis for patients.  
Bone metastases result when cancer cells spread from their site of origin (primary tumor) and 
settle in a bone to form a secondary cancer. This can affect only one area of the bone or 
several areas at any one time; complications of bone metastases include pain, increased risk of 
facture, hypercalcemia (abnormally high levels of calcium in the blood) and a decreased blood 
cell count. The most common cancer types that show tendency to metastasize in bone include 
prostate, breast, lung, kidney, thyroid cancer and multiple myeloma. One of the consequences 
of bone metastases results from a decrease of osteoblast number. Having reached the bone, 
malignant cells disrupt the remodeling process that normally occurs. Osteoclast number 
increase as tumor cells secrete factors such as parathyroid hormone related protein (PTHrP) 
that stimulates bone resorption and therefore gradually destroy it. This in turn results in the 
release of breakdown products such as TGF-β which stimulates the growth of malignant cells, 
thus perpetuating the destructive cycle and enhancing localized tumor growth. Recently 
improved understanding of these biochemical processes has prompted investigation into 
whether skeletal events in patients with malignant bone disease may correlate with levels of 
serum and urine markers of bone turnover, thus facilitating earlier detection or screening for 
such events. More than 90% of all metastases are found in the back, pelvis, upper leg, ribs, 
upper arm, and skull. The prognosis of cancers that metastasize to bone is in general very poor 
and the treatment for bone metastases tend to minimize the symptoms by reducing pain and the 
risk of fracture. The prevention and the development of therapeutic strategies against metastatic 
bone tumors lie in understanding the malignant cells preference in certain cancer types 
(prostate, breast, lung, kidney, thyroid cancer or multiple myeloma) to metastasize in bone 
tissue. Bone microenvironment may provide growth stimulating factors or others proteins that 
induce proliferation and angiogenesis of cancer cells allowing them to arrest the bone tissue. 
SPARC has been shown by several studies to be a key protein that attracts prostate cancer 
cells to bone microenvironment. [107-109]. One study showed that prostate cancer cells 
preferably migrated towards wild type bone extracts when compared to extracts obtained from 
SPARC null mice. This effect was reversed by restoration of SPARC. [107] The up-regulation of 
VEGF production by SPARC via αvβ3 and αvβ5 is a prostate cancer specific phenomenon, 
providing prostate cancer cells with significant growth advantage in bone. [108] Other work 
indicates that p45-sErbB3 (a soluble form of ErbB3, pooled in bone marrow supernatant 
samples from men with prostate cancer that had metastasized to bone) enhances the 
invasiveness of prostate cancer cells in part by stimulating the secretion of SPARC by bone. 
Thus p45-sErbB3 may mediate the bidirectional interactions between prostate cancer cells and 
bone. [110] 
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The development and progression of bone metastatic prostate cancer using SPARC-deficient 
mice infected with RM1 mouse prostate cancer cells showed that bone stromal SPARC 
inhibited prostate cancer expansion in bone through the regulation of osteoclast maturation and 
function. [111] Another report, by Podgorski et al., 2009, suggested that cathepsin K modulates 
the biological activity of SPARC in prostate cancer bone metastasis by cleaving it. In two tumor 
bone metastases cell lines (derived from clinical, PC3 and experimental MDA-231BO) 
enzymatic processing of SPARC was reduced by inhibition of cathepsin K. Moreover the 
presence of a cathepsin inhibitor reduces the GRO (growth-regulated oncogene) secretion, a 
pro-inflammatory and chemotactic factor regulated by SPARC. On the other hand, SPARC and 
cathepsin K overexpression and secretion raised GRO secretion. [112]  
In a recent study the effect of bone matrix SPARC on PC3 behavior was assessed by using 
murine osteoblast to create normal and SPARC-null bone matrix in vitro. The results of this 
study showed that when PC3 cells were grown on the wild type matrices, they presented 
decreased cell proliferation, increased cell spreading and decreased resistance to radiation-
induced cell death, compared to cells grown on SPARC null-matrix. [70] DeRosa CA et al. 
recently showed that SPARC gene was highlighted as a potential early marker of poorly 
differentiated phenotype of prostate cancers and the high SPARC expression at the time of 
prostatectomy was associated with the development of metastasis. [113] 
Based on the two separate transgenic models of prostate and breast cancer (transgenic 
adenocarcinoma of the mouse prostate and murine mammary tumor virus polyomamiddle T, 
respectively), using SPARC
-/-
 and SPARC
+/-
 mice, found that loss of SPARC had no significant 
impact on tumorigenesis. [114] Although the loss of SPARC, by itself, neither directly promoted 
nor inhibited spontaneous prostate or breast cancer progression, SPARC expression could be 
used as a potential prognostic biomarker of tumor severity and/or aggressiveness.  
SPARC might have an indirect effect on breast cancer cell metastasis in bone since its isolation 
from several sources such as osteoblasts or epithelial cells stimulated motility of human breast 
cancer cells and also enhanced the chemoattraction of breast cancer cells toward vitronectin (a 
known chemoattractant protein). [115] In another study a breast cancer cell line (MDA-231) 
deficient of SPARC was used in order to determine the endogenous effect of SPARC 
expression on invasion and metastasis of the breast malignant cells in bone. The induction of 
SPARC expression in MDA-231 cells did not affect the proliferation, apoptosis, aggregation or 
cell migration, but inhibited tumor cell invasion in vitro. Moreover, high expression of SPARC 
inhibited metastasis to different organs including lung and bone. Exogenous SPARC inhibited 
the platelet aggregation in vitro and the high expression of this protein in MDA-231 cells 
reduced tumor cell-induced thrombocytopenia in vivo in relation with control. In conclusion, a 
high endogenous SPARC expression seems to inhibit MDA-231 breast cancer metastasis by 
reducing the invasion activity and tumor cell-platelet aggregation. [116]  
As already mentioned, the survival rate in the case of patients with bone metastasis is very low. 
The understanding of cancer metastasis to bone should help the prevention of metastasis and 
the establishment of a valid therapy in order to improve the patient’s life quality and may 
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increase survival rates. It has been described that SPARC is associated to tumorigenicity and 
metastasis of cancer related bone metastasis like lung or melanoma cancers. [117, 118] 
Nevertheless, there are only few studies regarding prostate and breast cancers that tried to 
disclose the roles of SPARC in bone metastasis (table 3), and none associated with other 
cancer types that show a tendency to develop bone metastasis. 
 
 
2.5 - Conclusions and perspectives 
Considerable attempts have been made to produce adequate matrices or scaffolds that mimic 
bone ECM for applications in tissue engineering and regenerative medicine. In this context, 
several factors must be considered, such as the modification of biomaterial surfaces using 
growth factors, living bone cells or proteins, to guide cellular responses in bone remodeling, like 
osteoblast adhesion and long term functionality expressed as proliferation, synthesis of alkaline 
phosphatase and deposition of calcium containing mineral. [119] SPARC a matricellular 
glycoprotein associated with tissue remodeling, repair, development, cell turnover, is involved in 
bone formation, bone initiating mineralization process and collagen fibril assembly. [44, 62, 68-
70] The application of this protein could benefit the development of new valid therapeutic 
strategies for skeletal tissue regeneration. In addition, the research in this topic is essential 
since there are very few works involving SPARC and biomaterials for bone tissue regeneration. 
[73, 74] 
Furthermore, SPARC controls important mechanisms involved in cancer development and 
progression including the regulation of epithelial-to-mesenchymal transition, apoptosis, 
angiogenesis and also the regulation of the inflammatory response. SPARC is relevant in 
metastatic dissemination capacity of prostate, breast, lung, kidney, thyroid cancer and multiple 
myeloma cancer cells into bone tissue. Yet, the actual function of SPARC in tumorigenesis and 
tumor progression is still contradictory and not fully understood. There isn’t any review article 
addressing SPARC and cancer related bone metastasis. Depending on cancer type, different 
expression patterns and activities of SPARC may be found. This could be explained by the 
distinct tumor microenvironment established in different types of cancers that translates in terms 
of local composition of matrix molecules and cytokines and the protease profile. The different 
proteolytic products (peptide fragments) corresponding to different regions of SPARC have 
distinct activities and may explain the divergent and inconsistent biological activities observed 
with native full-size SPARC protein in distinct malignancies. SPARC peptide models could be a 
valid strategy to understand SPARC’s specific action in mechanisms that occur in tumor 
invasion and metastasis in bone tissue. Very few attempts, including SPARC peptides 
combined with chemotherapy and/or drugs, have been performed in this direction up to now. 
[49, 105, 120-122] 
Furthermore the differential function of SPARC in several types of cancers might be dependent 
upon whether it is expressed by the malignant cells themselves or by neighboring stromal cells. 
produced by non-malignant stromal cells. [97, 123, 124]  
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Table 3 - Studies related to SPARC activity in bone metastasis. 
Tumor type Expression Experimental approach Activity   Ref.  
Prostate  
High levels of SPARC at 
sites of bone metastasis 
Human  prostate cancer cell lines 
LNCaP, LNCaP-C4–2, PC3, and lacZ-
transfected CWR22R (H-clones) 
SPARC-null mouse model 
Attracts prostate cancer cells 
to bone; 
Increases VEGF production by 
metastatic cancer cells and 
integrin activation 
[107] 
High expression of 
SPARC in metastatic 
prostate cancer 
Transcriptomes of laser capture-micro-
dissected tumor cells with well- and 
poorly differentiated (PD) phenotype 
from primary prostate tumors of patients 
with 78 months of mean follow-up after 
radical prostatectomy.  
High SPARC expression at the 
time of radical prostatectomy 
is associated with an 
increased risk of tumor 
metastasis. SPARC gene was 
identified as a potential early 
marker of less favorable 
outcome associated with PD 
of prostate cancers. 
[113] 
SPARC expression is 
increased in prostate 
cancer metastases 
In vitro system composed by PC3 and 
mineralized matrices synthetized by wild 
type and SPARC-null osteoblasts. 
Bone matrix-associated 
SPARC attenuated the growth 
of PC3, increased cell 
spreading, and increased their 
sensitivity to ionization 
radioation. 
[70] 
A low glycosylated 
SPARC is highly 
abundant in bone 
  
In vitro studies using human prostate 
cancer cell lines (DU-145 and PC-3), 
several human prostate epithelial cell 
lines  as well as a HT1080 fibrosarcoma 
cell line and a B16-F10 mouse 
melanoma cell and extracts from various 
organs of mice and rat 
Enhances the invasion and 
migration by prostate cancer 
cells; 
Chemoattractant for bone-
metastasizing epithelial cells; 
Enhances matrix 
metalloprotease activity in 
prostate cancer cells  
[109] 
p45-sErbB3 up-
regulated the  
expression of SPARC 
Human prostate cancer cell lines 
(LNCaP and PC-3) 
Enhances the invasiveness of 
the prostate cancer cell lines 
PC-3 and C4-2B 
[110] 
Higher SPARC 
expression in bone 
metastasis compared to 
primary tumor 
SPARC deficient mice infected with 
SPARC-expressing syngeneic RM1 
mouse prostate cancer cells 
Inhibits prostate cancer 
expansion in bone through the 
regulation of osteoclast 
maturation and function 
[111] 
Breast 
  
In vitro MDA-231 breast carcinoma cell 
line study applying SPARC  derived from 
several sources  
(MDA-MB-435, MDA-MB-468), 
osteoblasts  (hFOB1.19), non-neoplastic 
breast epithelial (hTERT-HME1), and 
vascular endothelial cells isolated from a 
bone biopsy (HBME-1) 
Enhances breast cancer cells 
chemoattraction toward 
vitronectin 
[115] 
High SPARC expression 
in MDA-231 cells 
In vitro human cell line study using 
SPARC-negative MDA-231 breast 
carcinoma cell line infected with an 
adenovirus expressing SPARC;  
In vivo nude mouse model 
No effect on MDA-231 cell 
proliferation, apoptosis, cell 
aggregation, or migration; 
Inhibits breast cancer 
metastasis by reducing the 
invasion activity and tumor cell 
platelet aggregation in vitro; 
Reduces tumor cell-induced 
thrombocytopenia in vivo 
compared with control-infected 
cells 
[116] 
Prostate/ 
Breast  SPARC is significantly 
down regulated in 
highly metastatic human 
prostate cancer cells 
SPARC+/- and SPARC-/- mice using 
two separate transgenic mouse tumor 
models: transgenic adenocarcinoma of 
the mouse prostate (TRAMP) and 
murine mammary tumor virus polyoma 
middle T (MMTV-PyMT) 
No effect on prostate or breast 
cancer with the mouse tumor 
models tested  
Useful biomarker of 
aggressive, metastasis-prone 
tumors 
[114] 
up-regulation of SPARC  
both in vivo in 
experimental prostate 
bone tumors, and in vitro 
in co-cultures of bone 
marrow stromal cells 
with PC3 prostate 
carcinoma cells 
In vitro co-cultures of bone marrow 
stromal cells with prostate (PC3) and 
breast carcinoma cells (MDA-231BO)  
Severe combined immunodeficient 
(SCID) mice human/intrabone model 
Bone marrow cathepsin K 
regulates the biological activity 
of SPARC in prostate cancer 
bone metastasis  
[112] 
Chapter II 
 
 
34  
 
A series of studies have been performed in an attempt to elucidate the actual role of SPARC 
produced by non-malignant stromal cells. [97, 123, 124] SPARC knock-out mice showed low 
turnover osteopenia [57], intensive osteoclastogenesis [111] and matrices composed by thinner 
collagen fibers in random networks [70] that translated a less stroma and collagen deposition. It 
was proposed that SPARC is a critical component in the orchestration of the tissue 
microenvironment, important for metastatic cancer cells to grow and survive in the skeleton 
(skeletal cancer metastasis). In fact, the expression of many bone-enriched proteins, including 
SPARC by stromal cells in normal prostate and the up-regulation of VEGF production by 
SPARC being a prostate cancer specific phenomenon, contributes to the preference and 
significant growth advantage in bone-like environment by prostate cancer cells. Also the 
association between SPARC expression pattern and malignancy of prostate and breast cancers 
may contribute to the use of SPARC as a potential prognostic biomarker of tumor severity 
and/or metastasis. [113, 114] 
According to the works related to bone metastasis and presented in table 3, SPARC acts as 
protumorigenic and prometastatic protein, when expressed by stromal cells, trough 
enhancement of metalloprotease activity, VEGF production, or chemoattraction toward 
vitronectin. [107, 109, 110, 113, 115] On the contrary, when SPARC is produced by malignant 
cells, it inhibits cancer expansion through regulation of osteoclast maturation/function or by 
reducing platelet aggregation. The final outcome of SPARC function will undoubtedly be highly 
context dependent. [125] The development of SPARC-peptide models, conditional/gene 
inactivation models [95, 101, 126] or the transcriptional targeting using SPARC promoter [56, 
127-131] could be a valid strategy to understand how SPARC influences tumor invasion and 
metastasis and may lead to the development of anti-angiogenic, proliferation or counter-
adhesive therapeutic treatment against metastatic bone tumors. 
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Abstract 
This work aims to design a synthetic construct that mimics the natural bone extracellular matrix 
through innovative approaches based on simultaneous type I collagen electrospinning and 
nanophased hydroxyapatite (nanoHA) electrospraying using non-denaturating conditions and 
non-toxic reagents. The morphological results, assessed using scanning electron microscopy 
and atomic force microscopy (AFM) showed a mesh of collagen nanofibers embedded with 
crystals of HA with fiber diameters within the nanometer range (30 nm), thus significantly lower 
than those reported in the literature, over 200 nm. The mechanical properties assessed by 
nanoindentation using AFM exhibited elastic moduli between 0.3 and 2 GPa. Fourier 
transformed infrared spectrometry confirmed the collagenous integrity as well as the presence 
of nanoHA in composite. The network architecture allows cell access to both collagen 
nanofibers and HA crystals as in natural bone environment. The inclusion of nanoHA 
agglomerates by electrospraying to type I collagen nanofibers improved the adhesion and 
metabolic activity of MC3T3-E1 osteoblasts. This new nanostructured collagen-nanoHA 
composite holds a great potential for healing bone defects or as a functionally membrane for 
guided bone tissue regeneration and in treating further bone diseases. 
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1 - Introduction 
Considerable attempts have been made to produce adequate matrices or scaffolds that mimic 
the bone extracellular matrix (ECM) for applications in tissue engineering and regenerative 
medicine. These biomaterials should be specifically designed to be biocompatible, 
biodegradable and osteoconductive. Nanohydroxyapatite/collagen nanocomposites are ideal 
biomaterials for bone regeneration and target molecule delivery systems for the treatment of 
bone diseases. These types of biomaterials are suitable for bone contact and substitution, 
particularly novel natural polymer-based composites reinforced with bioactive components, such 
as nanophased hydroxyapatite (nanoHA) [1-5]. They represent the major inorganic and organic 
component assembly as in natural bone where the HA crystals of the mineral part are bound to 
collagen fibers, corresponding to 90-95 percent of the bone organic matrix. The mineral phase 
is responsible for providing adequate mechanical compressive strength, while collagen provides 
tensile properties. 
Electrospinning has recently attracted great interest in generating nanoscale fiber of 
biomaterials ranging from polymers and ceramics to their composite fibrous scaffolds for tissue 
engineering applications with fiber diameter ranging from a few microns to less than 100 nm [6, 
7]. This type of nanofibrous structure is regarded as a promising architecture in the sense that 
natural bone ECM exhibits collagen fibrils with diameters ranging from 20 nm to 40 µm [8, 9] 
which are far smaller than those that can be achieved with conventional processing methods.  
Natural polymers, including collagen, are very difficult to electrospin due to their high viscosity 
and low solubility in general organic solvents, as reported in most published work concerning 
the production of collagen fibrillar meshes [10-19]. For that reason, synthetic polymers such 
polyglycolic acid (PGA), polyL-lactic acid (PLLA), polylactic-coglycolic acid (PLGA) or 
polycaprolactone (PCL) are often added to collagen solution [20-22]. However, the chemicals 
(additives, traces of catalysts, inhibitors) or monomers (glycolic acid, lactic acid) released from 
polymer degradation may induce local and systemic host reactions that may cause clinical 
problems [23, 24]. Another way to overcome this problem is the use of organic toxic reagents, 
mainly highly volatile fluoroalcohols such as 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) and 2,2,2-
trifluoroethanol (TFE). However, these solvents are highly toxic and partially denaturate the 
native structure of collagen through the disruption of its characteristic triple-helical structure, 
decrease its denaturation temperature and result in a significant amount of collagen lost during 
electrospinning [25, 26]. Increasing efforts towards applying non-toxic aqueous systems, such 
as PBS/ethanol or acetic acid for medical applications have started to emerge [27-30]. In 
addition, post-fabrication crosslinking confers mechanical resistance through the binding of 
carboxylic groups in collagen fibrils, which is fundamental for in vitro assays and translation of 
these collagenous meshes in preclinical and clinical settings. In this work, we used N-ethyl-N'-
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[3-dimethylaminopropyl] carbodiimide/N-hydroxy succinimide (EDC/NHS) as a non-toxic 
crosslinker, despite most of the studies in the literature having applied toxic reagents such as 
glutaraldehyde [27, 31-35]. 
Here, we report an innovative approach based on two simultaneous methods, type I collagen 
electrospinning and nanophased HA electrospraying, using non-toxic reagents. Simultaneous 
electrospinning and electrospraying techniques have been applied to gelatin in only very few 
studies [36, 37]. The physicochemical properties of this biocomposite were investigated as well 
as its influence on MC3T3-E1 osteoblast cells performance in terms of morphology, adhesion 
and metabolic activity. This construct revealed to have a non-cytotoxic effect and ability to 
support osteoblast cell adhesion and viability. 
 
 
2 - Materials and Methods 
 
2.1 – Electrospinning and electrospraying 
Type I collagen, supplied by Kensey Nash (USA), was suspended in acetic acid: ethyl acetate: 
water (40:30:30) by stirring overnight at 4 ºC to obtain a 12 % (w v
-1
) collagen suspension. The 
solution was loaded into a syringe (5 mL) with a 21 G needle and electrospun at 0.1 mL h-
1
, 
under a high electrostatic field (20 kV) onto 12 mm diameter coverglasses attached on an 
aluminum foil wrapped on a rotating cylinder collector, at 400 rpm, placed at a distance of 120 
mm from the needle tip. Simultaneously, electrospraying of nanoHA, supplied by Fluidinova 
S.A. (Portugal), (nanoXIM•Hap102), was carried out. NanoHA 3.5% (v v-1) suspended in 
methanol was subjected to a set of ultrasonic cycles with amplitude of 60 A (20x15 ultrasonic 
pulses) in order to decrease nanoparticles agglomeration. The solution was loaded into a 
syringe (10 mL) with a 21 G needle and electrosprayed at 2 mL h
-1
, under a high electrostatic 
field (20 kV) onto the collagen fibers at a distance of 120 mm. The simultaneous electrospinning 
and electrospraying process was continuously performed during 1 h at room temperature (22 
°C) with a relative humidity of about 30-45%. Figure 1 illustrates the schematic diagram of the 
laboratory set-up used for the simultaneous electrospinning of collagen and electrospraying of 
nanoHA techniques. The samples obtained were subjected to chemical cross-linking in ethanol 
90 % (v v
-1
) containing 20 mM EDC and 10 mM NHS at 4 °C during 4 h in case of electrospun 
collagen fibers and 24 h in case of electrospun collagen fibers plus electrosprayed HA 
agglomerates. EDC, a zero-length crosslinker, causes a direct conjugation of carboxylates (–
COOH) to primary amines (–NH2) without becoming part of the final crosslink (amide bond) 
between target molecules. The cross-linked constructs were washed three times with ethanol 
90% (v v
-1
) and twice with water and dried overnight at room temperature in a desiccator before 
chemical and morphological characterization and cell culture studies. All the experimental 
conditions related to the weight % ratio of collagen-nanoHA, the proportion of reagents, and 
electrospinning/electrospraying conditions referred to previously were optimized in order to 
produce a stable network of collagen nanofibers and HA agglomerates (data not shown). 
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Figure 1. A schematic diagram of the laboratory set-up used for the simultaneous electrospinning and 
electrospraying techniques. 
 
 
2.2 – Substrates characterization 
The size of the HA agglomerates was determined using a Zetasizer Nano ZS (Malvern 
Instruments, U.K.), equipped with a 4 mW HeNe laser beam with a wavelength of 633 nm and a 
scattering angle of 173°. The size measurements were performed following the manufacturer’s 
instructions, at 25 °C in a polystyrene cell (ZEN0040), using the “General Mode” analysis 
model, which is suitable for the analysis of the majority of samples and dispersions. Size results 
were automatically calculated by the software, DTS Nano v.6.30, using the Stokes-Einstein 
equation. 
Chemical characterization of the developed structures was performed using Fourier transformed 
infrared spectroscopy (FT-IR), with a Perkin-Elmer 2000 FT-IR spectrometer. For this purpose, 
0.2 g of sample material (collagen, electrospun collagen fibers or composites of collagen and 
nanoHA obtained by simultaneous electrospinning and electrospraying) was ground and 
analyzed as KBr pellets at a spectral resolution of 4 cm
-1
. One hundred scans were 
accumulated per sample.  
The proportion of collagen and nanohydroxyapatite present in composites was assessed by 
Thermogravimetric analysis (TGA) using a NETZSCH Simultaneous thermal analysis (STA) 449 
F3 Jupiter
®
 instrument. Approximately 4.4 mg of sample was placed in an alumina sample 
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crucible and heated at 10 °C min
-1
 from 25 °C to 500 °C, under nitrogen atmosphere with a flow 
rate of 30 mL min
-1
. 
The surface characterization of substrates was examined using scanning electron microscopy 
(SEM). SEM analyses were performed using a FEI Quanta 400FEG/EDAX Genesis X4M 
(Hillsboro, OR, USA) scanning electron microscope under high vacuum conditions. The 
samples were sputter-coated with a thin palladium-gold film, using a sputter coater (SPI-
Module) in an argon atmosphere before observation. The diameters of twenty fibers randomly 
chosen from six different SEM images, each one corresponding to a distinct sample, were 
measured with a custom code image analysis implemented in the program ImageJ. The results 
referred to as diameter measurements, correspond to the average and median ± standard 
deviation (SD). The thicknesses of the collagen/HA biocomposites before and after chemical 
crosslinking were obtained through SEM image analysis. For both conditions, each sample 
(n=4) was placed in a container with liquid N2 and then a free fracture was produced under low 
temperature. The exposed fracture was observed by SEM under high vacuum, and images 
were produced with secondary electrons. For each sample, a total of four measurements were 
taken randomly. The results referred to as thickness measurements, correspond to the average 
± standard deviation (SD). 
Atomic Force Microcopy (AFM) studies were carried out using a Veeco Multimode NanoScope 
IVa scanning probe microscope. The surface topography of the collagen-nanoHA composite 
was imaged with a 16x16 µm
2
 piezo-scanner. Imaging analyses were performed at room 
temperature, in Tapping mode
®
, using a silicon cantilever with a spring constant of 25-75 N m
-1
 
(tip radius < 10 nm). Mechanical proprieties of electrospun ultra-thin non-woven collagen fiber 
mats before and after chemical cross-linking were determined by nanoindentation using a 
diamond-tipped probe cantilever with a resonance frequency of 60 kHz and a nominal spring 
constant of 131.0 N m
-1
 (DNISP; Veeco Probe, United States). For each sample, a total of 16 
nanoindentations were taken randomly. The time for both approach and retraction of the tip was 
set to 1.7s (1/0.6 Hz), with zero delay in between and a maximum load of 3 µN. All the 
measurements were taken in air and at room temperature. The Oliver and Pharr indentation 
model was applied to each load-unload curve, in order to obtain the elastic modulus or Young’s 
modulus parameter (E) [38]. For the calculations we assumed a Poisson coefficient of 0.2 for 
the collagen material (in fact, this model is not highly dependent on this coefficient). All 
calculations were performed using NanoScope v6.13 software.  
 
 
2.3 – In vitro cell culture studies 
MC3T3-E1 cells, established as an osteoblastic cell line from normal mouse calvaria, were 
grown in alpha minimum essential medium (α-MEM, Gibco) supplemented with 10% (v v
-1
) fetal 
bovine serum (FBS) (Invitrogen) and 1% penicillin-streptomycin (Gibco). Cells were cultured in 
75 cm
2
 plastic culture flasks, and incubated in a humidified incubator (37 °C and 5% CO2). 
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Freshly confluent MC3T3-E1 cells were rinsed with PBS, followed by incubation in trypsin/EDTA 
(0.25% trypsin, 1 mM EDTA; Sigma) for 10 minutes at 37 °C and then re-suspended in 
supplemented medium. The substrates were sterilized by immersion in a serial dilute ethanol 
solutions of 90, 70 and 50% (v v
-1
) during 10 min, and incubated with α-MEM during 30 min. 
After rinsing three times in PBS, the cells were seeded on both substrates (electrospun collagen 
fibers and collagen-nanoHA composites obtained by co-electrospinning/electrospraying) at a 
cell seeding density of 4x10
4 
cells/well. Coverglasses coated with Poly-D-lysine hydrobromide 
(PDL) were used as a control. MC3T3-E1 cells were cultured on both constructs for periods of 4 
h, 1, 4, 7, 14 and 21 days. For each material and culture period, six samples without cells were 
incubated with complete medium in the same way and used as blanks.  
The cell metabolic activity of MC3T3-E1 cells on substrates after 4 h, 1, 4, 7, 14 and 21 days of 
cell culture was evaluated using a resazurin-based assay [37]. Thus, 50 μL of resazurin (Sigma) 
at a concentration of 0.1 mg mL
-1
 were added to each well. After 3 h of reaction time, 100 μL of 
supernatant was transferred to the wells of a black-walled 96-well plate. Fluorescence was read 
using λex=530 nm and λem=590 nm in a microplate reader (Biotek, Synergy MX). The 
fluorescence value corresponding to the unseeded substrates was subtracted. The results 
correspond to the mean ± standard deviation of six cultured samples.  
The MC3T3-E1 cell distribution and morphology on the materials was assessed using confocal 
microscopy and SEM. For immunostaining of F-actin cytoskeleton and nuclei, the cell-seeded 
surfaces were rinsed twice with PBS and fixed with 4% para-formaldehyde for 15 min. After 
washing with PBS, cells were permeabilized with 0.1% Triton X-100 for 5 min and incubated in 
1% BSA for 30 min at room temperature. Cell cytoskeleton filamentous actin was visualized by 
treating the cells with Alexa Fluor
®
 594 Phalloidin (1:200 in BSA 1%, Molecular Probes
®
) for 20 
min in the dark. Finally the cells were washed with PBS and the cell nuclei were counterstained 
with 4’, 6-diamidino-2-phenylindole (Vectashield/DAPI) dye for 10 min in the dark. The images 
were acquired on a Leica SP5 confocal microscope (Leica Microsystems, Wetzlar, Germany) 
using a Plan-Apochromat 63 x oil objective. Images were processed and quantiﬁed using LAS 
AF v2.6.0.7266 software. Background noise was minimal when the optimal gain/offset settings 
for the detectors were used. Digital images were optimized for contrast and brightness using 
Adobe Photoshop (Adobe Systems, San Jose, CA). For SEM observation, cell-seeded samples 
fixed with 1.5% glutaraldehyde were dehydrated with a increasing ethanol water gradient and 
dried using hexamethyldisilazane. SEM analyses were performed using the same scanning 
electron microscope equipment described in section 2.2. Samples were sputter-coated with a 
thin palladium-gold film, using a sputter coater (SPI-Module) in an argon atmosphere before 
being observed. Samples were collected at days 1, 4, 7, 14 and 21 of MC3T3-E1 culture on the 
substrates. 
Statistical analysis was assessed using one-way ANOVA, with a significance level of p ≤ 0.05. 
GraphPad version 5.02 software was used to perform the analysis. 
 
 
Biocomposite for bone regeneration 
 
 
51 
 
3 - Results and Discussion 
 
3.1 - Substrates production and chemical-physical properties  
Both solubilization and electrospinning procedures have noticeable effects on collagen fiber 
diameter and morphology, namely, the flow rate, electrospinning voltage, needle and collection 
distance, and most critically, the concentration of collagen solution and solvent type. Previously, 
we tried to replicate the experimental conditions reported by the few published works that 
applied non-toxic aqueous solvents in the electrospinning of collagen, but without success. This 
was probably due to a different type I collagen origin and purity, as well as environmental 
conditions such as relative humidity of air, seldom mentioned, and temperature. Hence, the 
parameters of solubilization and electrospinning were optimized as described in section 2.1, in 
order to produce continuous collagen nanoscale-diameter fibers, the native structure of which is 
preserved, from an aqueous solution composed of acetic acid: ethyl acetate: water (40:30:30), 
embedded with crystals of HA. The addition of ethyl acetate improved the spinnability of the 
nanofibers and reduced the acidity of the solvent (acid acetic).[39] Since we wanted to preserve 
the nanometric scale of HA agglomerates resulting from the electrospraying technique, a 
nanoHA gel was used instead of nanoHA powder. This means that nanoHA did not undergo 
through a spray drying process, which typically enhances the degree of agglomeration of 
nanoHA particles. Also, the nanoHA solution was subjected to a set of ultrasonic cycles before 
the electrospraying process. The size of the HA agglomerates were assessed by Zetasizer 
Nano ZS. As expected, there was a steady decrease in size with increasing the number of 
ultrasonic pulses. Comparing the HA agglomerates size before and after ultrasonic pulse 
cycles, a reduction in size from 278 ± 30 nm to 126 ± 2 nm was observed. 
The collagenous integrity as well as the presence of nanoHA in nanostructured collagen-
nanoHA composite was confirmed by FT-IR. The spectrum of electrospun collagen nanofibers 
in Figure 2 depicts characteristic absorption bands at 1657, 1536 and 1241 cm
-1
, attributed to 
the amide I, II and III, respectively. The amide I absorption arises predominantly from protein 
amide C=O stretching vibrations, the amide II is made up of amide N-H bending vibrations and 
C-N stretching vibrations while the amide III arises predominantly from C-N stretching and N-H 
in plane bending from amide linkages. The integrity of collagen's triple helix can be evaluated by 
the ratio between the absorbance at 1235 and 1450 cm
-1
. Ratio values for denaturated collagen 
are around 0.5 and those for intact structures are around 1. For the analyzed samples, the 
value obtained was 1.07, indicating that the addition of nanoHA and the applied conditions did 
not destabilize collagen's triple helix. There was no band at 1706 cm
-1
, which suggests that 
there was no free acetic acid in the sample [40, 41]. Furthermore, the FT-IR spectrum of the 
collagen-nanoHA composites obtained using the simultaneous electrospinning and 
electrospraying techniques, in addition to the collagen characteristic bands referred to 
previously, revealed characteristic bands of nanophased HA, OH
- 
vibrational (633 cm
-1
) bands, 
and PO4
3-
 (3 ~ 1093 and 1032 cm
-1
; 1 ~ 962 cm
-1
, 4 601 and 564 cm
-1
) bands. The 
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characteristic bands of carbonate group can also be observed namely those corresponding to 
the 3 vibration of C-O (1452 cm
-1
) and the 2 vibrations (875 cm
-1
) [42]. 
 
 
Figure 2. FT-IR spectra of collagen, electrospun collagen and collagen-nanoHA composites obtained 
using the simultaneous electrospinning and electrospraying techniques. 
 
 
In order to quantify the amount of organic and inorganic components in the collagen-nanoHA 
composite, TGA measurements were carried out. TGA curves of the collagen-nanoHA 
composite showed weight loss in the range from room temperature to 100°C due to the 
evaporation of physisorbed water and weight loss between 250 and 500°C associated with the 
decomposition of collagen molecules (data not shown). Considering the residual mass values 
obtained by TGA, the inorganic content in the collagen-HA composite was 48.14 ±0.22 wt %. 
In addition to the Zeta sizer results, the nanometric scale of the nanoHA agglomerates was 
confirmed using SEM image analysis, (Figure 3, A (i)). The SEM images of the electrospun 
collagen revealed a random mesh of collagen nanofibers. The diameter measurement of twenty 
collagen fibers randomly chosen from six different SEM images, with a custom code image 
analysis implemented in the program ImageJ, allowed the calculation of average and median 
values, 37.2 ± 23.2 nm and 30.2 ± 23.2 nm, respectively (Figure 3, B). These diameter values 
are within the nanometer range and are significantly lower than those reported in the literature, 
which typically exceed 200 nm [14, 21]. It is interesting to note that collagen fibers obtained by 
electrospinning using organic toxic solvents the diameters of which are in the micrometer scale 
are often called collagen nanofibers, although in reality they are far beyond the nanometer 
scale. In addition, their diameters are substantially higher than the collagen nanofibers 
produced by electrospinning using acetic acid as the solvent and a low protein concentration as 
in our work or in Liu’s work [10, 13, 15, 17, 29]. In conclusion, the reason why the diameter of 
the collagen fibers obtained in this study is quite low when compared to previous studies, can 
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be attributed to the origin of collagen, its concentration, and most likely the type of solvents 
used and their v v
-1
 % which are distinct from all the other studies. Figure 3, A (iii) shows a 
representative SEM image of the collagen-nanoHA composites obtained using simultaneously 
electrospinning and electrospraying techniques. A random arrangement of collagen nanofibers 
and irregular structures of nanoHA incorporated between them may be observed.  
 
 
Figure 3. (A) SEM images of electrosprayed nanoHA (i), electrospun collagen nanofibers (ii) and collagen-
nanoHA composites obtained using the simultaneous electrospinning and electrospraying techniques (iii). 
(B) A histogram of the electrospun collagen fibers diameter distribution obtained using SEM. 
 
 
In this nano-network either collagen or nanoHA is accessible, resembling the ECM organization 
of bone tissue. Until now, all collagen-HA composites obtained by electrospinning were 
prepared from a mixture of collagen and hydroxyapatite. As a consequence, the composite 
surface is covered with collagen or HA, preventing direct cell/protein contact with both organic 
and inorganic components [15, 33, 43, 44]. The cross-linking procedure did not affect the 
morphological arrangement of the electrospun meshes. 
The thicknesses of the collagen-HA biocomposites before and after chemical cross-linking was 
determined based on SEM images, allowing the calculation of the average values 326 ± 115 nm 
and 376 ± 154 nm, respectively. There is no statistically significant difference between the latter 
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values, showing that the cross-linking procedure did not alter the physical structure proprieties 
in terms of thickness.  
AFM studies confirmed the nanoscale dimension of the collagen fibers, confirming the 
unprecedented resolution achieved with respect to the methodology used thus far [10, 14, 18, 
45, 46]. Moreover, the AFM images presented in Figures 4 A, B reveal a three-dimensional 
arrangement of collagen nanofibers. The ability of phase imaging AFM to distinguish samples 
with different surface viscoelastic properties enabled the visualization of the nanoHA 
agglomerates between the collagen nanofibers (Figure 4 B (ii)). 
 
Figure 4. Surface topography of the electrospun collagen nanofibers (A) and the collagen-nanoHA 
composite (B): height (i), phase (ii) and 3D (iii) images. All AFM images were obtained under Tapping 
mode
®
 (image scale 3 x 3 µm
2
). Arrows indicate nanoHA agglomerates. 
 
 
Young’s modulus (E) of uncross-linked collagen nanofibers, cross-linked collagen nanofibers 
and collagen-HA composite (Figure 5) was evaluated trough a nanoindentation test. The cross-
linking method and even the presence of nanoHA in the collagen-HA composite did not 
significantly affect the elastic modulus as shown in Figure 5 [47]. The Young’s moduli 
measured in this work were between 0.3 GPa and 2 GPa which are lower than the values 
reported in Wenger et al. work but identical to those reported by Heim et al. [48, 49]. 
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Figure 5. An example of an indentation curve (A) and Young’s moduli (B) of uncross-linked collagen 
nanofibers, cross-linked collagen nanofibers and cross-linked collagen-HA composites obtained by 
nanoindentation.  
 
 
3.2 – MC3T3-E1 morphology and metabolic activity 
The influence of both materials on MC3T3-E1 cell performance in terms of cell metabolic 
activity, cell distribution and morphology was investigated over a long period of cell culture, 21 
days with time points at 4 h, 1, 4, 7, 14 and 21 days. The pattern of metabolic activity in all the 
substrates was an increase with time of culture, indicating that both the collagen and 
biocomposite constructs presented a non-cytotoxic effect and had the ability to support 
osteoblast cell adhesion (Figure 6 (A)). Nevertheless, the metabolic activity of osteoblasts 
cultured on the electrospun pure collagen nanofibers revealed lower values compared to the 
control samples and the biocomposite constructs at the latter culture time points (4, 7, 14 and 
21 days). The inclusion of nanoHA agglomerates on type I collagen mesh induced proliferation 
of MC3T3-E1 osteoblasts after 4 days of cell culture. The calcium ions seem to promote the 
adhesion of bone cells and stimulate its subsequent activity, as suggested by other authors [43, 
44]. The analysis of cell metabolic activity at day 7 also suggests an increase of cell number on 
the nanostructured biocomposites. Once population capacity was reached, we hypothesize that 
a small number of cells might go through apoptosis as part of the regular cell life cycle, 
nevertheless metabolic activity on the control and electrospun biocomposites never ceased to 
grow, reaching identical values. 
The cell distribution and morphology of MC3T3-E1 on the materials were followed by SEM and 
confocal imaging at the different time points of the cell culture, the results being in accordance 
with the metabolic activity data. At 4 h of cell culture, MC3T3-E1 cells were attached and were 
spread out across the surface, demonstrating a characteristic elongated shape with fusiform 
fibroblastic appearance (Figure 6 (B) and Figure 7). In particular, in Figure 7 it is interesting to 
observe that the MC3T3-E1 cells cultured on the collagen-HA constructs seem to interact with 
both the organic and inorganic components without any preference. They completely adhered to 
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the surface, closely binding the filopodia to the substrates and reaching a fusion state, making it 
difficult to distinguish, at some points, between parts of the cell (filopodia, products secreted by 
cells, and their ECM) and the substrate material (meshes of collagen nanofibers and HA 
agglomerates). 
 
 
Figure 6. Metabolic activity (A) and morphology and cytoskeletal organization (B) of MC3T3-E1 cells 
cultured on the electrospun collagen nanofibers and collagen-nanoHA composites obtained using the 
simultaneously electrospinning and electrospraying techniques versus time. In (A) the results are 
expressed in terms of relative fluorescence units (RFU); in (B) F-actin is indicated in red while the cells’ 
nuclei were counterstained in blue with DAPI dye. MC3T3-E1 cells cultured on coverglasses coated with 
PDL were used as the control. Values are the average ± SD of six cultures. * indicates a statistically 
significant difference from the control cultures. § indicates a statistically significant difference from the 
cultures grown  on the electrospun collagen nanofibers (p ≤ 0.05). 
 
 
A compact film of cells was formed after 4 days of cell culture, rendering it almost impossible to 
observe individual cells among so many others widespread in several cell layers. 
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Figure 7. SEM images of MC3T3-E1 cells cultured on the electrospun collagen nanofibers and collagen-
nanoHA composites obtained using the simultaneous electrospinning and electrospraying techniques 
versus time. MC3T3-E1 cells cultured on coverglasses coated with PDL were used as control. 
 
 
4 - Conclusion 
In this work a novel composite based on collagen nanofibers and nanoHA agglomerates was 
successfully obtained using co-electrospinning/electrospraying. The collagen integrity as well as 
the nanoscale dimensions of both the biocomposite components (collagen and nanoHA) were 
preserved as confirmed by FTIR spectra, and SEM, and AFM images analysis. In the 
development of the construct, water-based solvents (ethyl acetate, acid acetic and water) and 
non-collagen denaturating conditions were applied. The diameters of the electrospun collagen 
nanofibers, estimated from the SEM images to range between 10 and 100 nm, are far below 
those stated in the literature, thus offering a roadmap to obtain a further level of biomimicry in 
matrix design strategies. This novel construct allows cell access to both collagen nanofibers and 
HA crystals as happens in the natural bone micro-and nano-environments. Regarding cellular 
interactions, these structures were cytocompatible and able to withstand adhesion and growth 
of MC3T3-E1 osteoblasts in the long-term. This new collagen nanofibers-nanoHA composite is 
an excellent biomaterial candidate for bone tissue regeneration with conditions similar to human 
ECM, as well as in biomedical applications in small bone defects and for coating the surfaces of 
others materials with a mechanical support function. 
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Abstract  
Most aggressive prostate cancer (PCa) types tend to metastasize frequently to bone and 
SPARC, a matricellular protein, might participate in such biological processes. The objective of 
this study was to evaluate the effect of SPARC in prostate carcinogenesis and bone 
metastization. This was explored assessing the morphology, metabolic activity and SPARC 
expression of different PCa cell lines resembling different stages of carcinogenesis, using a 3D 
bone-biomimetic model (collagen nanofibers/nanohydroxyapatite) grafted with SPARC. Our 
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findings highlight distinct cellular behavior depending on cell type and presence of exogenous 
SPARC. In fact, SPARC addition contributed to the survival and significant growth of a non-
bone metastatic PCa cell line (LNCaP) on bone-like biomaterial.  
Moreover, SPARC expression levels were evaluated in a series of prostatic tissues, comparing 
normal prostate, pre-neoplastic prostate intraepithelial neoplasias and overtly malignant tumors, 
and also metastasis to its correspondent primary prostate tumors, ascertaining potential 
association between SPARC and clinicopathological data. Remarkably, SPARC was 
overexpressed in patients with higher Gleason Score, indicating tumors with poor prognosis, as 
well as in metastasis, particularly from bone sites, compared with their respective primary 
tumors. The results suggest a potential role of SPARC as a clinical target on PCa, due to its 
association with bone metastization. 
 
 
Keywords: SPARC, prostate cancer, 3D bone-biomimetic biomaterial, bone metastasis, 
Quantum dots, Gleason Score. 
 
 
1 - Introduction  
Prostate cancer (PCa) is the second most incident cancer in men worldwide (31.1%), ranking 
first in incidence in the US (27%)
1
. PCa is a heterogeneous disease, ranging from clinical 
indolent to extremely aggressive disease, causing substantial morbidity and mortality
2
. If PCa is 
locally confined, the 5-year survival rate is nearly 100%. However, this type of cancer shows a 
unique metastatic dissemination pattern, exhibiting preference for bone in about 80% of cases, 
developing bone metastasis as only site of progression
3
. In this scenario, the prognosis for 
patients with PCa that has spread to bone is very poor, mostly incurable. Adequate 
management is, thus, mandatory to avoid overtreatment and sub-optimal, ineffective therapy. 
Understanding the biological mechanisms underlying PCa onset and progression might 
contribute to improve the existing clinical approaches and therapeutic decisions. SPARC 
(secreted protein, acidic and rich in cysteine) also known as osteonectin or BM-40 is a 
multifunctional glycoprotein belonging to the matricellular proteins group
4, 5
. It is known that his 
protein can disrupt cell adhesion to the extracellular matrix (ECM) promoting morphological 
changes, cell differentiation, proliferation, regulation of matrix metalloprotease production and 
collagen fibril assembly
6-8
. SPARC controls important mechanisms involved in cancer 
development and progression including regulation of epithelial-to-mesenchymal transition, 
apoptosis, angiogenesis and inflammatory response, being relevant in PCa cells metastatic 
dissemination ability into bone tissue
9, 10
. Nevertheless, SPARC’s contribution in such biological 
processes is poorly understood and controversial
11
. Cellular microenvironment holds an 
important role in tumor progression. In fact, it has been suggested that bone microenvironment 
provides growth-stimulating factors for PCa cells, being SPARC a key protein to attract these 
tumor cells to the bone
9, 12-14
. Development and progression of bone metastatic PCa using 
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SPARC-deficient mice infected with RM1 mouse PCa cells showed that bone stromal SPARC 
inhibited tumor expansion in bone through osteoclast maturation and activity regulation 
15
. Chen 
showed that PCa cells preferably migrate towards wild type bone extracts when compared to 
extracts obtained from SPARC null mice. This effect was reversed by SPARC restoration
3
. 
Despite all these data concerning SPARC association with PCa, there is still plenty to known, 
especially due to the importance of morbidity and mortality of bone metastasis in PCa patients. 
Currently, 3D cell culture models such as, matrigel, xenograft transplantation or rotary cell 
culture have been designed to study the impact of the tumor microenvironment on cancer 
cells
16-21
 
Here we propose the development of a 3D bone-like model as a strategy to understand the 
involvement of SPARC in bone metastization. This is the first study assessing the cellular 
response, and SPARC expression of different prostate cancer cell lines (PC-3, LNCaP and 
VCaP) cultured on a SPARC functionalized collagen/nanohydroxyapatite biocomposite 
resembling bone ECM. PCa cell lines deriving from different stages of prostate carcinogenesis 
were chosen to understand SPARC’s specific activity in cell/material interactions and in PCa 
bone metastasis. To the best of our knowledge this is also the first report on the consulted 
literature where QDs were directly functionalized by chitosan-SPARC bioconjugates aiming at 
bioimaging and internalization towards tumor cells. SPARC expression was also evaluated in a 
large prostate tissues series from both normal and tumor samples, ascertaining potential 
associations between SPARC and relevant clinicopathological data. This study combining PCa 
cells and 3D bone biomimetic model in vitro analysis, should provide insight into SPARC 
relevance for prostate carcinogenesis, seeking to fill the gap on literature concerning this 
thematic.  
 
 
2 - Materials and Methods  
 
2.1 - Reagents and protein solutions 
Cadmium perchlorate hydrate (Aldrich, USA, Cd(ClO4)2·6H2O), sodium sulfide (Synth, Brazil, 
>98%, Na2S·9H2O), sodium hydroxide (Merck, USA, ≥99%, NaOH), acetic acid (Synth, Brazil, 
≥99.7%, CH3COOH), 1-ethyl-3-[3-(dimethylamino)propyl] carbodiimide hydrochloride (EDC) 
(Sigma, USA,  98%, C8H17N3·HCl, MW=191.7 g.mol
-1
), and N-hydroxysulfosuccinimide sodium 
salt (NHS) (Aldrich, USA,  98%, C4H4NNaO6S, MW=217.1 g.mol
-1
), were used as received. 
Chitosan powder (Aldrich Chemical, USA, catalog#448869, low molecular weight, MW = 50-190 
kDa, lot supplied=60-70 kDa; degree of deacetylation DD≥ 75.0%, lot supplied = 96.1%; 
viscosity 20–300 cPoise, lot supplied =35 cPoise, 1 wt.% in 1% acetic acid) was used as the 
reference polysaccharide ligand. Secreted Protein Acidic and Rich in Cysteine (SPARC) human 
recombinant, expressed in CHO cells, (Sigma-Aldrich, Schnelldorg, Germany, Ref. SRP3159) 
solutions were prepared by dilution in ultra-pure water with 18.2 MΩ.cm resistivity at 
concentrations of 10 µg/mL and 50 µg/mL for further use.  
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2.2 - 3D bone-biomimetic biomaterial  
The design and characterization of the 3D bone-like model used in this study is presented in a 
previous report
22
. Briefly, its design used an innovative approach combining type I collagen 
electrospinning and nanohydroxyapatite (nanoHA) electrospraying onto 10 mm diameter 
coverglasses, using collagen non-denaturating conditions and non-toxic reagents. The 
substrates were chemically cross-linked, using 20 mM EDC and 10 mM NHS (both from Fluka, 
BioChemika, Switzerland) before cell culture studies. Their topography reflects a mesh of 
collagen nanofibers containing nanoHA agglomerates between them.  
 
 
2.3 - Patients and sample collection 
Primary tumors from 194 patients harboring clinically localized prostate adenocarcinoma were 
prospectively collected after diagnosis and primary treatment with radical prostatectomy, at 
Portuguese Oncology Institute-Porto (IPO-Porto), Porto, Portugal. Additionally, 27 prostatic 
intraepithelial neoplasias were collected (PIN). A set of 15 morphologically normal prostate 
tissues (MNPT) were obtained from prostatic peripheral zone of bladder cancer patients 
submitted to cystoprostatectomy. Ten prostate metastases and correspondent primary tumors 
were also studied. All tissue specimens were promptly frozen immediately after surgery. Upon 
histological confirmation of tumor or normal prostate tissue, fresh-frozen tissue fragments were 
trimmed to enhance the yield of target cells (>70%). Histological slides from formalin-fixed 
paraffin-embedded tissue fragments were also routinely obtained from the same surgical 
specimens and assessed for both Gleason score and TNM stage. 
23, 24
  
Relevant clinical data were collected from the clinical charts. Informed consent was obtained 
from all participants, according to institutional procedures. This study was approved by the 
institutional review board [Comissão de Ética para a Saúde-(CES-IPOFG-EPE 295/2013)] of 
IPO-Portuguese Oncology Institute - Porto, Portugal. 
 
 
2.4 - Cell culture 
 
2.4.1. PCa cell lines 
Human PCa cell lines (22Rv1, DU145, LNCaP, MDA-PCa 2b, NCI-60, PC-3 and VCaP) and a 
non-malignant prostate cell line (RWPE-1) were maintained in recommended medium 
supplemented with 10% (v/v) fetal bovine serum (Gibco, Invitrogen, Carlsbad, CA, USA) and 
1% of penicillin-streptomycin (Gibco), at 37º C and 5% CO2 in a humidified chamber. All cell 
lines were routinely tested for contamination by Mycoplasma spp. using a specific multiplex 
PCR (PCR Mycoplasma Detection Set, Clontech Laboratories Inc., Mountain View, CA, USA). 
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2.4.2. Cell seeding on biomaterial surface 
Scaffolds were sterilized by immersion in sequential 90, 70 and 50% (v/v) ethanol/water 
solutions. Before cell seeding, substrates were pre-incubated with SPARC (10 µg/mL and 50 
µg/mL) for 60 minutes. Cells were seeded on biocomposites at a density of 4x10
4 
cells/mL for 
LNCaP and PC-3 cell lines and 12x10
4 
cells/mL for VCaP. Cells were cultured for 1, 7 and 14 
days. Samples without cells were incubated with complete medium and used as blanks. 
Coverglasses coated with Poly-D-lysine hydrobromide (PDL) (Sigma-Aldrich) were used as 
control. 
 
 
2.4.3. Cell metabolic activity 
Cell metabolic activity of PCa cells on scaffolds after 1, 7 and 14 days of cell culture was 
assessed using a resazurin-based assay
25
. Briefly, 10% (v/v) resazurin solution was added onto 
each well. After 3 hours at 37ºC, fluorescence was measured using λex=530 nm and λem=590 
nm in a microplate reader (Biotek, Synergy MX, BioTek® Instruments, Inc., Winooski, VT, USA). 
The fluorescence value corresponding to the non-seeded substrates was subtracted. Results 
correspond to the mean ± standard deviation of six cultured samples. 
 
 
2.4.4. Cell morphology  
PCa cells distribution and morphology onto biomaterial was assessed using laser scanning 
confocal microscopy and scanning electron microscopy (SEM). For immunostaining the cell-
seeded surfaces were fixed with 4% para-formaldehyde, permeabilized with 0.1% Triton X-100 
and incubated in 1% BSA for 30 minutes at room temperature (RT). Cell cytoskeleton 
filamentous actin was visualized by using Alexa Fluor
®
 594 Phalloidin (1:200 in BSA 1%, 
Molecular Probes
®
 Karlsruhe, Germany) and cell nuclei were counterstained with 4’, 6-
diamidino-2-phenylindole (Vectashield/DAPI) dye. Images were acquired on a Leica SP5 
confocal microscope (Leica Microsystems, Wetzlar, Germany) using a Plan-Apochromat 20x 
and 40x oil objectives and were processed and quantified using LAS AF v2.6.0.7266 software. 
Background noise was minimal when the optimal gain/offset settings for the detectors were 
used. Digital images were optimized for contrast and brightness using Adobe Photoshop 
(Adobe Systems, San Jose, CA). For the SEM observations, cell-seeded samples fixed with 
1.5% glutaraldehyde were dehydrated with an increasing ethanol–water gradient and dried 
using hexamethyldisilazane.  
SEM analyses used a FEI Quanta 400FEG/EDAX Genesis X4M (Hillsboro, OR, USA) scanning 
electron microscope under high vacuum conditions. Samples were palladium–gold coated, 
using a sputter coater (SPI-Module) in argon atmosphere before observations. 
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2.5 - SPARC functionalization  
 
2.5.1. Quantum dots synthesis 
Quantum dots (QDs) were prepared at the Center of Nanoscience, Nanotechnology, and 
Innovation-CeNano
2
I, Federal University of Minas Gerais, Brazil. Briefly, SPARC was 
bioconjugated with chitosan using EDC as a “zero-length” crosslinking agent in the presence of 
sulfo-NHS. Novel CdS nanoconjugates were synthesized using chitosan-SPARC (Ch_SPARC) 
as biofunctional capping ligand and chitosan (Ch) as the reference through an aqueous route in 
a reaction flask at RT based on a similar procedure previously published
26
. CdS QDs colloidal 
solutions referred as QD_Ch and QD_Ch_SPARC (10.92 µg/mL) were dialyzed for 24 hours.  
 
 
2.5.2. Characterization of the CdS QD conjugates 
UV-Visible spectroscopy measurements were conducted using a spectrometer (Perkin-Elmer 
equipment, Lambda EZ-210) in transmission mode and wavelengths from 600 nm to 190 nm. 
All experiments were conducted in triplicates and data was presented as mean ± standard 
deviation. Photoluminescence characterization was based on spectra acquired at RT using a 
violet diode laser module at excitation = 405 nm (150 mW, Roithner LaserTechnik, GmbH) 
coupled to USB4000 VIS-NIR spectrophotometer (Ocean Optics). All tests had a minimum of 
four repetitions (n≥4). Digital colour images were collected from visible QDs fluorescence 
(λexcitation = 254 nm, “darkroom-chamber”).  
QD-bioconjugates nanostructural characterization, based on images and selected area electron 
diffraction patterns (SAED) were obtained using a Tecnai G2-20-FEI transmission electron 
microscope (TEM) at 200 kV. Samples were prepared by dropping the colloidal dispersion onto 
a carbon grid. QD size was obtained based on the TEM images using an image processing 
program (ImageJ, version 1.44, public domain, National Institutes of Health). 
 
 
2.5.3. Internalization assay 
LNCaP cells were seeded at 4x10
4
 cells/mL on cover glasses coated with PDL and incubated 
for 24 hours at 37°C and 5% CO2. Different concentrations of QD_Ch and QD_Ch_SPARC 
solutions (0.5 %, 5 %, and 50 %) were added to the cell media and incubated at 37°C and 5 % 
CO2 for 1 hour. After PBS washing, cells were fixed with 4% paraformaldehyde, permeabilized 
with 0.1% Triton X-100 and the cellular cytoskeleton was stained using Alexa Fluor
®
 488 
Phalloidin (1:40 in BSA 1 %, Molecular Probes
®
). Confocal microscope was used to detect cells 
fluorescence using laser irradiation at 405 nm and 488 nm to excite QDs and the Phalloidin, 
respectively. As control, cells were seeded on cover glasses with only complete medium.  
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2.5.4. Quantitative Flow Cytometry Analysis  
LNCaP cells were seeded at 50x10
4
 cells/mL in TCPS 24 well-plates, and incubated for 24 
hours at 37 °C and 5 % CO2. Cells were incubated with different concentrations of QD_Ch and 
QD_Ch_SPARC solutions (0.5 %, 5 %, 20 % and 50 %) for 1 hour. Afterwards, cells were 
detached with trypsin/EDTA (0.25 % trypsin, 1 mM EDTA; Sigma), fixed with 4% para-
formaldehyde, and suspended in PBS for analysis. A flow cytometer (BD FACSCanto™ II, BD 
Bioscience) equipped with a 405 nm violet laser was used, and the chosen fluorescence 
detectors for the QD were Pacific Blue-A and PCA-A. To quantify cell uptake, the median of cell 
fluorescence distribution (X-mean) from each experiment was normalized to X-mean of the non-
treated control. TCPS wells seeded with cells, without QDs, were used as unstained control. 
 
 
2.6 - SPARC expression from clinical samples and PCa cell lines 
Endogenous expression of SPARC in PCa cell lines was assessed by transcript levels and 
protein evaluation. Similar procedure was followed to evaluate the biomaterial’s impact in 
SPARC expression from LNCaP, VCaP and PC-3 cells cultures. Cell lines were seeded on 
substrates and control samples at a density of 20x10
4
/mL for 7 and 14 days. 
 
 
2.6.1. Total RNA extraction 
Total RNA from clinical samples and cell lines was obtained by suspension in TRIzol® reagent 
(Invitrogen, Carlsbad, CA, USA) and after adding chloroform, total RNA was purified using the 
PureLink™ RNA Mini Kit (Invitrogen). RNA concentration, purity and samples integrity were 
determined on a Nanodrop ND-1000 spectrophotometer (NanoDrop Technologies, Wilmington, 
DE, USA). 
 
 
2.6.2. SPARC expression in clinical samples and cell lines 
A total of 300 ng RNA were reverse transcribed and amplified using TransPlex Whole 
Transcriptome Amplification Kit (Sigma–Aldrich) and purified QIAquick PCR Purification Kit 
(Qiagen, Hilden, Germany). SPARC relative expression values were normalized using the 
expression levels of 18S. Each plate included multiple non-template controls and serial dilutions 
of a cDNA from human prostate RNA (Ambion, Invitrogen) to establish a standard curve for 
each plate. All experiments were run in triplicate. 
 
 
2.6.3 Immunohistochemistry 
Histological slides from formalin-fixed paraffin-embedded (FFPE) 4 μm thick tissue fragments of 
5 samples of MNPT, 20 of primary PCa and 9 metastasis were obtained from the previously 
referred specimens. Briefly, after deparaffinization, antigen retrieval was performed by heating 
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in an antigen unmasking solution (EDTA buffer) (Vector Laboratories, Peterborough, United 
Kingdom). Protein detection was performed using the Novolink™Max Polymer Detection 
System (Leica Biosystems, Nussloch, Germany). Slides were incubated overnight with a rabbit 
anti-human SPARC polyclonal antibody, (Sigma-Aldrich, Ref. HPA002989, directed against the 
extracellular domain of SPARC) in a 1:100 dilution at 4ºC and all washing steps were performed 
with Tris buffered saline with Tween® 20 (TBS-T) (Sigma-Aldrich). Antigen-antibody binding 
reaction was unveiled by incubation for 7 minutes, in the dark, in a 0.05% (m/v) 3,3’-
diaminobenzidine (DAB) solution (Sigma-Aldrich) in phosphate-buffered saline (PBS) (Biochrom 
Ltd., Cambridge, United Kingdom). Finally, slides were counterstained with Hematoxylin (EMD-
Millipore) and dehydrated and cleared. Positive control was FFPE tissue from a colorectal 
cancer.  
Slides were observed by an experienced pathologist for SPARC immunoexpression. The 
scoring criteria were: 0 – no observed expression; +1 – weak expression; +2 – moderate 
expression; +3 – intense expression. Moreover, cases with a +1 score were considered 
negative for SPARC expression, and cases with a +2 or +3 score were considered as positive. 
 
 
2.7 - Statistical analysis 
The Shapiro-Wilk’s W test allowed for checking the appropriateness of a normal distribution 
assumption for each of the parameters (data not shown). Comparisons between two groups 
were performed using the non-parametric Mann–Whitney U-test, and between multiple groups 
using Kruskal-Wallis. Statistical analysis specifically for metabolic activity data was assessed 
using nonparametric one-way ANOVA. Bonferroni´s correction was used in all statistical tests 
with multiple groups. P-values were considered statistically significant when below 0.05. 
Statistical analysis SPSS 20.0 for Mac (IBM-SPSS Inc., Chicago, IL, USA) was performed and 
graphs were built using GraphPad Prism 5.0 software for Mac (GraphPad Software Inc., La 
Jolla, CA, USA). 
 
 
3 - Results  
 
3.1 – PCa cell adhesion and metabolic activity when cultured onto SPARC grafted 
biomaterial 
The biomaterial’s network architecture allows cells to access both collagen nanofibers and HA 
crystals, as it occurs naturally in bone environment. The effect of exogenous SPARC grafted on 
biomaterial surface and the biomaterial itself on LNCaP, PC-3 and VCaP cells performance in 
terms of cell’s metabolic activity, distribution and morphology was investigated after 1, 7 and 14 
days of cell culture, as presented in Figures 1, 2 and 5. 
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3.1.1. PC-3 cells 
The cellular metabolic activity of PC-3 cells increased with the culture time for all substrates, 
indicating that the biocomposite was non-cytotoxic and able to support PC-3 cell adhesion 
[Figure 1 (a)]. PC-3 cells cultured on biomaterial revealed higher metabolic activity than control 
after 7 and 14 days. The presence of exogenous SPARC did not induce any differences in the 
metabolic activity of these cells cultured, and this was independent of the SPARC concentration 
at the biomaterial. A higher SPARC concentration (100 µg/mL) was also tested but did not 
altered PC-3 cells metabolic activity as well (data not shown). For representative purposes the 
lowest SPARC concentration is shown (10 µg/mL) [Figure 1 (b)]. Regarding the characterization 
of PC-3 morphology at day 1, cells were attached and spread-out across the surface, with 
characteristic spherical or spindle-shaped appearances. Cells formed a compact film after 7 
days on both structures.  
 
 
Figure 1 - Metabolic activity (a), morphology and cytoskeletal organization (b) followed by confocal and 
SEM imaging of PC-3 cells cultured on the collagen/nanoHA composites without protein adsorption and 
with SPARC (10 µg/mL) pre-adsorption versus time. In (a) the results are expressed in terms of relative 
fluorescence units (RFU); in (b) F-actin is indicated in red while the cells’ nuclei were counterstained with 
DAPI (blue). PC-3 cells cultured on coverglasses coated with PDL were used as control. Scale bar: 50 μm. 
Values are the average ± SD of six cultures. * indicates a statistically significant difference from the control 
cultures (p≤0.05). 
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Particularly on collagen/nanoHA surfaces, due to several cell layers formation, individual cells 
were difficult to observe, contrarily to control surfaces where cells did not proliferate as much 
[Figure 1 (b)].  
 
 
3.1.2. LNCaP cells 
 
3.1.2.1. Cell metabolic activity and cell morphology 
The cellular metabolic activity of LNCaP cells growing on the controls surfaces was significantly 
higher than on the biomaterial surfaces, especially for the later culture timepoints [Figure 2 (a)]. 
SPARC pre-adsorption on scaffolds (50 µg/mL) induced statistically significant increase in 
LNCaP metabolic activity compared to non-functionalized biocomposites, for all timepoints 
tested. LNCaP cells cultured on 2D structures were spread-out with spindle-like morphology, 
while for 3D cultures, they adopted a rounder morphology with less extended cytoskeleton 
[Figure 2 (b)]. Although on both structures LNCaP cells were highly proliferative and formed 
aggregates, cell distribution was slightly different. At day 14, control surfaces revealed a 
heterogeneous mat of individual cells coating the space between cell clusters, while in 3D 
cultures, LNCaP cells were exclusively arranged as sets of compact cell masses leaving the 
remaining surface almost empty. As for metabolic activity results, SPARC functionalized 
surfaces presented better cell coverage than non-modified biomaterials. 
 
 
3.1.2.2. Quantum dots characterization  
In Figure 3 (a), the UV-Vis spectrum of QD_Ch_SPARC conjugate colloidal suspension is 
shown after their stabilization. The curve exhibits a broad absorption band between 350 to 450 
nm with the excitation absorption peak (exc) at approximately 387±3 nm. This behavior is 
attributed to the nucleation/growth of CdS nanoparticles within the “quantum confinement 
regime” based on the, so-called, “blue-shift” observed for the curve, compared to the “bulk” 
value (Figure 3 (a), arrow at = 512 nm). The average CdS nanoparticle size of 2.3±0.2 nm was 
determined using Henglein’s empirical model
27
, which relates the diameter of the CdS 
nanoparticle (2R) to the exc transition onset. The optical band gap (absorbance onset, EQD = 
2.72 eV) and the “blue-shift” (0.30 eV) values were determined from the absorption coefficient 
data versus wavelength, using the “Tauc relation” (curve not shown) extracted from the UV-Vis 
spectra
28
, providing strong evidence that CdS QDs were effectively produced and stabilized by 
chitosan-SPARC conjugates in aqueous medium at RT because the band gap energy of the 
semiconductor (2.72 eV) was significantly greater than in bulk CdS (i.e., 2.42 eV)
26
.  
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Figure 2 - Metabolic activity (a), morphology and cytoskeletal organization (b) followed by confocal and 
SEM imaging of LNCaP cells cultured on the collagen/nanoHA composites without protein adsorption and 
with SPARC (10 µg/mL and 50 µg/mL) pre-adsorption versus time. In (a) the results are expressed in 
terms of relative fluorescence units (RFU); in (b) F-actin is indicated in red while the cells’ nuclei were 
counterstained with DAPI (blue). LNCaP cells cultured on coverglasses coated with PDL were used as 
control. Scale bar: 50 μm. Values are the average ± SD of six cultures. * indicates a statistically significant 
difference from the control cultures. § indicates a statistically significant difference from the cultures grown 
on the non-functionalized biocomposites (p≤0.05).  
 
 
The photoluminescence spectrum of the nanoparticle-bioconjugate system is present in Figure 
3 (b). From a general perspective, band edge recombination was not detected, and other bands 
were observed at approximately 495-570 nm (green) and within the 600-750 nm range (orange-
red). These results are in agreement with the reported emission spectra of CdS nanoparticles 
synthesized in aqueous medium at RT under metal atoms excess and these emissions are 
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associated with intrinsic defects. The green emission is due to metal atoms entering the lattice 
at interstitial sites, Cdi, and the broad orange-red band is related to interstitial atoms and 
vacancies defects (VCd-VS and VS)
29-31
. Green luminiscence was chosen for the biological tests 
due to its intense emission peak. 
TEM image of CdS QDs capped by the chitosan-SPARC is showed in Figure 3 (c). The 
QD_Ch_SPARC nanoparticles were spherical with a relative monodisperse distribution and size 
in reasonable agreement with the values obtained from the UV-Vis optical absorbance showed 
in Figure 3 (a). Therefore, TEM results indicated that CdS QDs were properly stabilized by the 
bioconjugate. 
 
 
Figure 3 - Characterization of CdS QDs. UV-Vis (a) and PL (b) spectra of QD_Ch_SPARC. (c) Typical 
TEM image of CdS conjugates. (Inset I: schematic representation of chitosan-SPARC stabilized CdS QDs 
ligand; Inset II: green luminescence of QDs; Inset III: detail of QD_Ch_SPARC size and lattice fringes 
obtained by TEM/SAED. 
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3.1.2.3. Internalization assay and Flow cytometry analysis 
LNCaP cells were able to internalized QD_Ch_SPARC as displayed by confocal imaging in 
Figure 4 (c). Their uptake efficiency was quantified by flow cytometry, where LNCaP cells 
showed a fluorescent positive population with average intensities ~40 times higher than control 
for cells incubated with QD_Ch_SPARC (50%). The cell positive population is indicated in 
Figure 4 (b), showing 1% positive cells at 5% QD_Ch_SPARC concentration and 20.5% and 
37.7% for 20 and 50% of QD_Ch_SPARC concentrations, respectively. 
 
 
Figure 4 - Internalization of the bioconjugate QD_Ch_SPARC. LNCaP cells were incubated with different 
concentration of QD_Ch_SPARC (0.5%, 5%, 20% and 50%) for 1hour and probe internalization was 
assessed by flow cytometry (a and b) and laser scanning confocal microscopy (c). In (a) representative 
graphs of the quantitative flow cytometric analyses (QD positive - Pacific Blue and PCA-A channels) are 
shown; in (b) the quantification of the fluorescence is expressed as the median of the cell fluorescence 
distribution of each system (X-mean) normalized based on the untreated control (X-mean of TCPS). (C) 
Representative image of LNCaP cells incubated with QD_Ch_SPARC, shown as the orthogonal projection 
of a Z-stack (of a total of 6 images). Yellow arrows show internalized QD_Ch_SPARC. Cell cytoskeleton is 
shown in red (λexc: 488 nm) and QD_Ch_SPARC is shown in green (λexc: 405 nm). Scale bar: 50 μm.  
 
 
3.1.3. VCaP cells 
In the case of the VCaP cells, the metabolic activity pattern on control structures increased with 
culture time and was superior to the biomaterial’s one, for all timepoints [Figure 5 (a)]. 
Moreover, SPARC adsorbed on biomaterial surfaces significantly affected VCaP cells behavior 
by decreasing metabolic activity and adhered cells number. Particular at day 14, metabolic 
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activity values corresponding to the functionalized biomaterials were lower than those found at 
day 7. The highest SPARC concentration induced a statistically significantly lower cell metabolic 
activity than for non-modified biomaterial. Regarding cell morphology [Figure 5 (b)], VCaP cells 
preferably adopted a cell cluster shape on both 2D and 3D structures.  
 
 
Figure 5 - Metabolic activity (a), morphology and cytoskeletal organization (b) followed by confocal and 
SEM imaging of VCaP cells cultured on the collagen/nanoHA composites without protein adsorption and 
with SPARC (10 µg/mL and 50 µg/mL) pre-adsorption versus time. In (a) the results are expressed in 
terms of relative fluorescence units (RFU); in (b) F-actin is indicated in red while the cells’ nuclei were 
counterstained with DAPI (blue). VCaP cells cultured on cover glasses coated with PDL were used as the 
control. Scale bar: 50 μm. Values are the average ± SD of six cultures. * indicates a statistically significant 
difference from the control cultures. § indicates a statistically significant difference from the cultures grown 
on the non-functionalized biocomposites (p≤0.05). 
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Cell aggregates number increased with time only for 2D samples. Also, on 2D, single VCaP 
cells spread-out with both round and spindle-like morphologies, establishing a cell monolayer 
between the compact cell aggregates. SPARC grafted biomaterial surfaces were much less 
populated and with smaller cell agglomerates compared to the non-functionalized biomaterial. 
These data corroborate the metabolic activity pattern. 
 
 
3.2 - SPARC expression on prostate cell lines 
SPARC expression was evaluated on several prostate cell lines [Figure 6 (a)]. RWPE-1 
immortalized normal prostate epithelial cell line was used as control. Strikingly, all PCa cell lines 
displayed lower levels of SPARC expression than RWPE-1, except PC-3 cells that showed 8 
fold increased expression than control. 
 
 
3.3 - SPARC expression on PCa cells cultured onto biomaterial 
LNCaP cells cultured on control samples exhibited higher levels of SPARC expression than on 
bone-like biomaterial, for both timepoints being statistically significant at 7 days of culture 
(p=0.002) [Figure 6 (b)]. Regarding PC-3 cells, no statistically significant differences were found 
between both analyzed substrates [Figure 6 (c)]. VCaP cells on biomaterial led to increased 
SPARC expression compared to control, statistically significant at day 7 (p=0.002) [Figure 6 (d)].  
 
Figure 6 – SPARC expression levels from prostate cell lines cultured in wild-type conditions (a) and from 
LNCaP (b), PC-3 (c) and VCaP (d) cultured on the collagen/nanoHA composites. In (a) the results are 
displayed after normalization to RWPE-1. In (b), (c) and (d) PCa cells cultured on coverglasses coated with 
PDL were used as the control. (** p< 0.01; * p< 0.05; ns – non-significant). 
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3.4 - SPARC expression on prostate clinical samples 
 
3.4.1. Differential expression among prostate clinical groups 
SPARC expression was also evaluated in different prostate tissues, ranging from normal 
prostate (MNPT), to pre-neoplastic prostate intraepithelial neoplasias (PIN) and overtly 
malignant tumors (PCa). No statistically significant differences were found among the analyzed 
groups, although high heterogeneity in SPARC expression levels was found within prostate 
adenocarcinomas [Figure 7 (a)]. Also a subset of these samples went through 
immunohistochemistry evaluation of SPARC presence (Table 2). Protein expression was again 
very heterogeneous as for mRNA levels, and both normal epithelial and tumoral cells displayed 
similar levels. 
 
 
3.4.2. Association between SPARC expression and clinicopathological data 
The clinicopathological data of the used samples are displayed in Table 1. By analyzing the 
expression levels of SPARC in prostate clinical samples we found that there was no association 
of SPARC expression with the pathological stage, age or the prostate-specific antigen (PSA) 
levels. However, when classifying the samples following the Gleason Score in three categories 
(<7, 7, >7), the more aggressive category (>7) displayed higher SPARC expression levels (vs 
<7, p=0.005; vs 7, p=0.038) [Figure 7 (b)].  
 
Table 1 - Clinical and pathological features of patients included in validation. 
  PCa MNPT 
Number of patients, n  194 15 
Age (yrs), median (range) 64 (49-75) 64 (45-80) 
PSA levels (ng/mL), median (range) 8.1 (2.66-35.5) n.a. 
Pathological stage, n (%)    
pT2  108 (55.7) n.a. 
pT3a 65 (33.5) n.a. 
pT3b 21 (10.8) n.a. 
Gleason Score, n (%)    
< 7 65 (33.5) n.a. 
= 7 114 (58.8) n.a. 
>7 15 (7.7) n.a. 
PCa, Prostate carcinoma; MNPT, Morphologically normal prostate tissue; n.a., not applicable 
 
 
3.4.3. SPARC expression on primary tumors and matched metastasis 
Ten primary prostate tumors and corresponding metastasis samples were studied. It was found 
that 6 of these metastases displayed higher levels of SPARC expression than their tumor 
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counterparts [Figure 7 (c)]. Moreover, a bone metastasis from the orbit displayed the highest 
values for all samples tested in this set. Nine of these samples were also tested for 
immunoreactivity, as displayed in Figure 7 (d/e). 
 
 
Figure 7 - Expression levels of SPARC in prostate clinical samples (a), in PCa samples stratified by 
Gleason score (b) and in paired metastasis and PCa primary tumors (line at 1 represents PCa primary 
tumor as normalizer for each sample) (c). (** p< 0.01; * p< 0.05; ns – non-significant). 
Immunohistochemical stain for SPARC expression in prostatic tissue. Primary tumor (d) and lymph node 
metastasis (e) protein reactivity. 
 
 
In general, metastasis displayed higher SPARC protein levels than their primary tumor 
counterparts (Table 3). Moreover, as for the rest of clinical samples group’s and as in mRNA 
analysis, heterogeneity was the most prominent feature. 
 
 
Table 2. Immunohistochemical expression of SPARC in prostate cancer and morphological 
normal prostate tissues (MNPTs). 
 Negative Positive 
Total (N) 
Clinical Sample Group Weak (+1) Moderate (+2) Intense (+3) 
Prostate cancer 9 (81.8%) 2 (18.2%)  11 
MNPTs 1 (20.0%) 4 (80.0%) - 5 
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Table 3. Immunohistochemical expression of SPARC in metastasis and correspondent primary 
prostate tumors. 
 Negative Positive 
Total (N) 
Clinical Sample Group Weak (+1) Moderate (+2) Intense (+3) 
Metastasis 4 (44.4%) 4 (44.4%) 1 (11.1%) 9 
Primary PCa 6 (66.7%) 3 (33.3%) - 9 
 
 
4 - Discussion 
In this study, the interaction of several prostate cancer cell lines, resembling different stages of 
carcinogenesis (PC-3, LNCaP and VCaP) with a 3D bone-biomimetic model and the 
matricellular protein SPARC was assessed. It highlighted distinct cell behavior depending on 
PCa cell line type and presence of exogenous SPARC. 
As expected, PC-3 cells growth on bone-like biomaterial was significantly higher than on control 
cultures. This specific interaction can be explained as PC-3 cells have high affinity to the major 
bone protein, collagen type I (Col-I) through expression of two Col-1 binding integrin receptors 
(α1β1 and α2β2)
32
. Moreover, these cells produce factors involved in normal skeletal 
development and osteoblastic activity by modifying the bone microenvironment, such as 
urokinase-type plasminogen activator and PSA, contributing to disseminate cancer cells into 
bone
33
. No significant differences were observed in metabolic activity and morphology of PC-3 
cells through addition of exogenous SPARC, divergently from that reported by Shin et al 
13
 
where 1.0 µg/mL SPARC decreased the total number of cell nuclei. The high endogenous levels 
of SPARC in these cells, might explain the absence of effect on their behavior when exogenous 
SPARC was added. 
Regarding LNCaP cell line, deriving from a non-bone metastatic site, cell distribution and 
morphological features differed between 2D and 3D cultures. LNCaP cells cultured on 3D 
biomaterials were arranged in multicellular colonies resembling in vivo tumors, whereas single 
cells adopted a rounder morphology than monolayer cells found on 2D structures. Our results 
are in accordance with Sieh’s work, where LNCaP cells cultured on polyethylene glycol 
hydrogels had different cellular response to androgen stimulation between 2D and 3D 
environments
34
. Moreover, exogenous SPARC might have compensated for very low SPARC 
expression levels in LNCaP and contributed to increasing metabolic activity and number/size of 
compact cellular agglomerates observed in SPARC modified bone-biomimetic constructs. 
Indeed, LNCaP cells were able to internalize SPARC as proved by using a new fluorescent bio-
nanoprobe of SPARC bioconjugate with QDs (QD_Ch_SPARC). According to quantitative flow 
cytometry analysis, the cell fluorescent positive population rose with increasing QD_Ch_SPARC 
concentration with average intensities of ~40 times higher than control. Additionally, SPARC 
regulates signaling integrins and their ability to interact with ECM components
13, 35, 36
. Shin et al. 
showed that exogenous SPARC repressed PCa cells proliferation and migration mediated by 
interaction with integrin β1 and consequently suppression of AKT phosphorylation
13
. The up-
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regulation of VEGF production by SPARC via αvβ3 and αvβ5 is a PCa specific phenomenon, 
providing a significant advantage to PCa cells to grow inside bone
14
. Importantly, LNCaP cells 
lack integrins expression
37
, thus exogenous SPARC addition appears to contribute to the 
survival and significant growth in bone-like environment of non-bone metastatic PCa cells. 
VCaP cell line derives from a vertebral metastatic lesion of a patient with hormone refractory 
disease and has a mutation in TP53 gene
38
. These cells cultured onto biomaterial showed 
significantly increased SPARC’s expression compared to control. Moreover the exogenous 
SPARC presence decreased cellular colonies number and size, particularly over 14 days of 
culture, being in accordance with the metabolic activity data. Herein, SPARC seems to act as a 
counter-adhesive protein by disrupting cell–matrix interactions and preventing cell spreading
39
. 
Tumor protein p53 acts as a tumor suppressor and its expression decreases cell migration by 
SPARC transcriptional down-regulation
40, 41
. Also, SPARC controls cell proliferation and cell 
cycle progression through the p53/p21 pathway
42
. Therefore, in VCaP cells TP53 mutation 
might compromise the cross-talk between this protein and SPARC, promoting SPARC up-
regulation and massive cell detachment from the surface. This requires further study, to clarify 
its validity. An exhaustive evaluation of SPARC expression was performed on prostate cell lines 
and primary and metastatic prostatic tumors. Although several studies have been published, the 
data available is rather conflicting. In 2000, Thomas et al. reported that PC-3 displayed low 
expression levels while VCaP presented a higher expression values with LNCaP results 
between both
12
. In this work, on the contrary, PC-3 was the most expressing cell line followed 
by control cell line (RWPE-1) that exhibited higher expression levels than all PCa cell lines. This 
pattern was also observed in the clinical prostate tissues, where slightly higher SPARC 
expression was found in morphologically normal prostate tissues than for prostate tumors that 
presented extremely heterogeneous levels SPARC expression levels. These results are in 
agreement with Shin’s that reported a more frequent expression of SPARC in normal prostate 
tissues than in tumor tissues, although without statistical significance
13
. Strikingly, this is the first 
time that a significant differential expression in patients with different Gleason Scores is 
reported. SPARC expression is progressively increased in tumors from low to high Gleason 
Scores. According to the World Health Organization, Gleason Score enables the prediction of 
PCa natural history and assessment of recurrence risk after treatment, reflecting progressive 
loss of glandular structures and stroma invasion
2, 23
. In fact, 6 out of the 10 metastasis analyzed 
exhibited higher levels of SPARC than their primary tumors and the only bone metastasis 
available displayed the highest SPARC levels. Contrarily to most other studies, normal prostatic 
tissues derived from patients not harboring PCa were analyzed, avoiding potential 
contamination during specimen collection and nucleic acid extraction. This approach ensures 
that all differences found between MNPT and PCa are real.  
Protein analysis by immunohistochemistry disclosed and confirmed high heterogeneity across 
samples, and that expression is similar between normal epithelia and tumor cells. However 
when comparing primary tumors and the corresponding matched metastasis for protein 
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presence the latter displayed higher SPARC levels. This suggests the relevance of SPARC in 
prostate carcinogenesis later stages, specifically in the metastatic process. 
In summary, the different outcomes upon exposure to the biomaterial shown by three different 
cell lines is corroborated by the SPARC’s expression heterogeneity found in clinical samples. 
Furthermore, in vitro studies demonstrated that depending on the cancer cell line type, the 
expression pattern of SPARC varies spatially and temporally. This may justify for each PCa cell 
line, the preference for and significant growth advantage in different in vivo tumor 
microenvironments.  
Regarding clinical samples, there was no difference between PCa and normal samples in 
protein and mRNA analysis. Nonetheless, SPARC expression was significantly higher in 
patients with higher Gleason Score, associated to poorer prognosis, and protein expression 
also increased in metastatic samples when compared with their matched primary tumors. 
Summing-up, it seems likely that SPARC is involved in the later stages of prostate cancer 
progression and therefore related to metastization, as suggested from our in vitro assays. 
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CHAPTER V 
 
Concluding remarks and future perspectives 
 
 
1 – Concluding remarks 
 
 
Nanohydroxyapatite/collagen nanocomposites are ideal biomaterials for bone regeneration and 
target molecule delivery systems for the treatment of bone diseases. Such types of biomaterials 
are suitable for bone contact and substitution, particularly novel natural polymer-based 
composites reinforced with bioactive components, such as nanoHA. [1-5] In the present PhD 
project an innovative biocomposite that mimics the structure of extracellular matrix (ECM) of 
trabecular bone structure was successfully developed. Its design included simultaneous type I 
collagen electrospinning and nanophased hydroxyapatite electrospraying using water-based 
solvents (ethyl-acetate, acetic acid and water) under non-collagen denaturating conditions, as 
an alternative to the common practice of using toxic reagents or adding synthetic polymers to 
the collagen solution that could lead to local or systemic host reactions by chemicals/monomers 
released from polymer degradation. [6-12] The network architecture reflects an interwoven 
mesh of collagen nanofibers incorporating aggregates of calcium phosphate crystals, allowing 
cell access to both collagen nanofibers and HA crystals as in natural bone environment, as 
opposed to all collagen–HA composites previously described, that were prepared by 
electrospinning mixed solutions containing collagen and hydroxyapatite, resulting in composite 
surface covered with undifferentiated collagen or hydroxyapatite. [13-16] The collagen 
nanofibers diameter values ranging between 10 and 100 nm, are far below the ones stated in 
the literature, thus offering a roadmap to obtain a further level of biomimicry to matrix design 
strategies. [8, 17] Regarding cellular interactions, these structures were cytocompatible and 
able to withstand adhesion and growth of MC3T3-E1 osteoblasts in a long-term. The inclusion 
of nanoHA agglomerates by electrospraying to type I collagen nanofibers improved adhesion 
and metabolic activity of MC3T3-E1 osteoblasts. The calcium ions seem to promote the 
adhesion of bone cells and stimulate its subsequent activity, as suggested by other authors [43, 
44]. This new collagen nanofibers/nanoHA composite appears as an excellent biomaterial 
candidate for bone tissue regeneration due to its similarity with human ECM, as well as in 
biomedical application for filling small bone defects and coating of other load-bearing materials 
surfaces. 
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The combination of biomaterials and tissue culture techniques enables the development of 3D 
in vitro models aiming at recreation of the native tumor microenvironment to be used in 
screening oncologic drugs and studying cancer cell biology. Indeed, the development of these 
3D tissue-engineered tumor models could be a valid strategy to understand the complex 
mechanisms that occur in tumorigenesis, angiogenesis, tumor invasion and metastasis in bone 
tissue. [18-22] Another novelty of the present work resides in studying the relevance and impact 
of SPARC (secreted protein, acidic and rich in cysteine) in prostate carcinogenesis and bone 
metastization, using the new biocomposite mimicking natural bone extracellular matrix as a 3D 
bone-like in vitro model. In this approach, distinct cell lines deriving from different stages of 
prostate carcinogenesis were cultured on this bone biomimetic in vitro model functionalized with 
SPARC. Each PCa cell line type displayed a distinct cellular response to the same substrate 
and to the presence of exogenous SPARC, resembling the cellular performance found in vivo 
tumor microenvironments. [23] Herein, PC-3, a highly proliferative bone-metastatic cell line, 
showed a great affinity and advantage in growing in this 3D scaffold similar to bone ECM, 
without needing exogenous SPARC. [24] On the contrary, the presence of exogenous SPARC 
contributed to the survival and significant growth of a non-bone metastatic PCa cell line 
(LNCaP) on bone-like construct. The addition of exogenous SPARC might have compensated 
for very low SPARC expression levels in LNCaP, providing a significant advantage growth on a 
bone-like biomaterial through regulation of signaling integrins and interaction with ECM 
components. [25-28] Furthermore, LNCaP cells were able to internalize SPARC as proved by 
the novel use of a new fluorescent bionanoprobe of SPARC bioconjugate with QDs. An 
exhaustive evaluation of SPARC expression was performed on human prostate cell lines and in 
an extensive series of prostatic tissue samples from both normal and tumor samples 
ascertaining potential associations between SPARC and relevant clinicopathological data. 
Although several studies have been published, the data available is rather conflicting. [27, 29] In 
this particular work, PC-3 was the most expressing cell line followed by control cell line (RWPE-
1) that exhibited higher expression levels than all PCa cell lines. This pattern was also observed 
in the clinical prostate tissues, where slightly higher SPARC expression was found in 
morphologically normal prostate tissues when compared to tumor tissues that presented 
extremely heterogeneous levels of SPARC expression. However when comparing primary 
tumors and the corresponding matched metastasis for protein presence, the latter displayed 
higher SPARC levels, particularly in the case of bone metastasis. It is important to notice, that 
SPARC expression was progressively increased in tumors from low to high Gleason Scores. 
According to the World Health Organization, Gleason Score enables the prediction of PCa 
natural history and assessment of recurrence risk after treatment, reflecting progressive loss of 
glandular structures and stroma invasion. Indeed, a significant differential expression in patients 
with different Gleason Scores is reported in this work, which had not been previously presented 
in the literature. Summing-up, the distinct outcomes upon exposure to the biomaterial shown by 
different PCa cell lines is corroborated by the SPARC’s expression heterogeneity found in 
clinical samples. Nonetheless, SPARC expression was significantly higher in patients with 
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higher Gleason Score, associated to poorer prognosis, and protein expression also increased in 
metastatic samples when compared with their matched primary tumors. Altogether these results 
indicate that SPARC is involved in the later stages of PCa progression and therefore related to 
bone metastization, thus supporting SPARC potential role as a clinical target on prostate 
cancer. 
 
The unique technology involved in the production of the referred biomaterial combined with its 
unique features and capabilities, such as, ready accessibility of both collagen and calcium 
phosphate, ability to be modulated to different settings or ability to be easily functionalized with 
active agents, led the need to protect it via a patent application: The PCT Application 
WO2015/162559 A1 entitled “mesh composition for repairing or the regeneration of tissues and 
methods thereof”. 
 
 
2 - Future perspectives 
 
The innovative biomaterial developed as described in chapter III is a promising candidate to be 
used in regeneration and reconstruction of bone tissue or to be applied as a model for in vitro 
scientific experiments to understand the mechanisms associate to metastatic dissemination 
capacity of prostate cancer cells into bone. However a number of issues still need to be studied 
in detail, thus further studies should be considered as future work. Some strategies that could 
eventually be envisaged are described below according to the intended application purpose.  
The various parameters involved in the production of the referred biomaterial can be easily 
handled in accordance with a specific purpose. In particular, these structures can be resized to 
the desired scale in the form of two-dimensional structures such as membranes, films, coatings 
on other materials, or as three-dimensional structures (Scaffolds). The alignment of collagen 
fibers would be an interesting modification to be introduced in order to study the influence of this 
new arrangements in cell behaviour namely in guided tissue regeneration. Also another aspect 
to be explored is the ability of these collagen/nanoHA structures to be functionalized with active 
agents (i.e. proteins, growth factors) that have affinity for collagen or calcium phosphate and 
interfere with important biological mechanisms. The choice of these proteins or others 
molecules depends on the application for which it is intended. SPARC is a matricellular 
glycoprotein associated with tissue remodelling, repair, development, cell turnover, bone 
mineralization as well as several activities affecting tumours growth and progression, namely in 
cancer-related bone metastases such as in prostate cancer. [30-33] Yet, its actual role in bone 
regeneration is not fully understood and is very contradictory in bone metastasis. The broad 
range of activity of the different regions of SPARC may well explain the divergent and 
inconsistent biological activities observed with the native full-size SPARC protein in different 
malignancies, as different proteolytic products (peptide fragments) would exert diverse effects 
on cellular behaviour. [34-37] Eventually, this may lead to the development of SPARC-peptide 
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models as potential therapies in the treatment of bone diseases such as prostate cancer 
metastasis. Another objective to be followed would be the development of a novel osteoblast-
prostate cancer cell co-culture model in order to study their crosstalk in a 3D controlled 
microenvironment simulating the in vivo tumor microenvironment. In addition, considering the 
seemingly relation between hormonal dependance and SPARC expression among PCa cell 
lines, it would be interesting to study by additional techniques the interaction of SPARC in a 
serum supplemented with androgens in these cell lines. Thereby, the development of osteoblast 
prostate cancer cell co-culture model, SPARC‐peptide models or conditional/gene inactivation 
models, together with hormonal regulation (androgens) could be a set of valid strategies to 
understand how SPARC may influence anchorage, proliferation and apoptosis of osteoblasts 
and SPARC null osteoblasts, and in malignant cells as well as in migration and invasion of 
prostate cancer cells. This may be promising in bone tissue regeneration and in the 
development of anti-angiogenic, anti-proliferative or counter-adhesive treatment approaches 
against metastatic bone tumours. 
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